Autoimmune Polyendocrinopathy

Autoimmune MONDO:0017278 Pathograph 24 Show in embeddings browser Autoimmune disorder of endocrine system Polyendocrinopathy

Autoimmune polyendocrinopathy is an umbrella for syndromes in which at least two endocrine glands develop autoimmune failure, often with non-endocrine autoimmunity. This entry retains the traditional MONDO-linked types 1-4 while making their unequal biology explicit: type 1 (APS-1/APECED) is a monogenic AIRE-deficiency disorder, whereas adult types 2-4 are clinical combinations with polygenic immune susceptibility. Organ-specific autoantibodies are clinically useful diagnostic and predictive markers, but autoreactive T cells rather than the antibodies are considered the principal tissue-damaging effectors in well-studied endocrine components. Detailed APS-1 phenotyping is curated separately in Autoimmune_Polyendocrine_Syndrome_Type_1.yaml; this file emphasizes shared mechanisms, classification boundaries, surveillance, and cross-subtype evidence.

Ask OpenScientist

Ask a research question about Autoimmune Polyendocrinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
5
Pathophys.
9
Phenotypes
5
Gaps
24
Pathograph
4
Genes
4
Medical Actions
4
Subtypes
4
Differentials
3
Datasets
4
Trials
1
Models
22
References
📘

Definitions

1
Clinical umbrella definition
Autoimmune polyglandular disease is defined clinically by two autoimmune-induced endocrine failures. Individual type definitions then depend on the component diseases and, for APS-1, the monogenic context.
CASE_DEFINITION
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"Autoimmune polyglandular diseases (APD) are defined as the presence of two autoimmune -induced endocrine failures."
This review states the disease-level clinical definition used for the umbrella entry.
◆

Subtypes

4
Type 1 (APS-1/APECED) MONDO:0009411
Monogenic, usually childhood-onset autoimmune polyendocrinopathy caused by biallelic AIRE deficiency. Chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency form the classic triad. A separate disease entry contains the detailed APECED phenotype and management model; here APS-1 is retained to connect it to the broader umbrella.
Show evidence (1 reference)
PMID:33958142 SUPPORT Human Clinical
"APS type 1 presents with hypoparathyroidism, mucocutaneous candidiasis and Addison's disease. It is caused by AutoImmune Regulator (AIRE) gene mutation."
The review defines the classic APS-1 component diseases and AIRE basis.
Type 2 (Schmidt syndrome) MONDO:0010012
Adult/polygenic syndrome centered on primary adrenal insufficiency with autoimmune thyroid disease and/or type 1 diabetes. HLA and immune-regulatory alleles modify risk but are not sufficient causes.
Show evidence (1 reference)
PMID:33958142 SUPPORT Human Clinical
"SPA type 2 presents with Addison's disease, type 1 diabetes, or autoimmune thyroid disease. Multiple genes have been implicated, including those of the class II major histocompatibility complex."
This supports the component-disease and polygenic framing of type 2.
Type 3 MONDO:0016422
Autoimmune thyroid disease with another autoimmune disorder, excluding Addison disease and hypoparathyroidism under the traditional classification. It is a clinical-combination category rather than a single established molecular etiology.
Show evidence (1 reference)
PMID:33958142 SUPPORT Human Clinical
"SPA type 3 is characterized by autoimmune thyroid disease and other autoimmune disease, excluding Addison's disease and hypoparathyroidism, 4 genes have been implicated and confer susceptibility."
This states the traditional inclusion and exclusion boundary for type 3.
Type 4 MONDO:0016423
A residual traditional category for combinations of autoimmune endocrine disease not assigned to types 1-3. Its boundaries depend on the classification system and should not be interpreted as a unified mechanism.
Show evidence (1 reference)
PMID:12050123 SUPPORT Human Clinical
"Autoimmune AD presented in four forms: as APS type 1 (13% of the patients), APS type 2 (41%), APS type 4 (5%), and isolated AD (41%)."
This clinical series documents use of the type 4 category without implying a distinct molecular cause.
?

Discussions and Knowledge Gaps

5
Should autoimmune polyendocrinopathy continue to use the traditional types 1-4 as one classification, or should monogenic immune-dysregulation syndromes such as IPEX be integrated as peer APS types?
CONTROVERSY OPEN autoimmune_polyendocrinopathy_classification_boundary
Attached to
has_subtypes#Type 1 has_subtypes#Type 2 has_subtypes#Type 3 has_subtypes#Type 4
The traditional four-type scheme is embedded in MONDO and adult endocrine literature, but newer pediatric reviews use a three-group framework of APS-1, APS-2, and IPEX. These groupings mix molecular etiologies and clinical combinations, so subtype counts are classification-dependent rather than a settled natural taxonomy.
Show evidence (2 references)
PMID:36980146 SUPPORT Human Clinical
"Three types of APSs are reported, including both monogenic and multifactorial, heterogeneous disorders."
This recent review explicitly uses a three-type pediatric framework.
PMID:33958142 SUPPORT Human Clinical
"SPA type 3 is characterized by autoimmune thyroid disease and other autoimmune disease, excluding Addison's disease and hypoparathyroidism"
This review documents continued use of the traditional type 3 category.
For each component endocrinopathy, which autoantibodies are predictive or diagnostic biomarkers, and which—if any—directly mediate tissue injury rather than marking a T-cell-driven response?
INTERPRETATION OPEN organ_autoantibody_biomarker_vs_effector
Attached to
biochemical#Organ-specific endocrine autoantibodies pathophysiology#Organ-Specific Autoreactive T-Cell Effector Injury
Collapsing all autoantibodies into one destructive mechanism overstates evidence and obscures the functionally distinct APS-1 anti-cytokine antibodies. Antigen-, organ-, and stage-specific longitudinal studies are needed to separate prediction from effector causality.
Proposed experiments
Prospective paired autoantibody and autoreactive T-cell study
prospective longitudinal immune-phenotyping study Relation: this experiment is of type this experiment type This experiment is of type prospective longitudinal immune-phenotyping study.
exp_aps_component_antibody_tcell_longitudinal
Enroll antibody-positive patients before gland failure and repeatedly measure antibody titer/function, antigen-specific CD4/CD8 repertoires, gland-function tests, and clinical conversion. Test whether antibody changes add causal or predictive information beyond T-cell responses.
Decision criterion
Distinguish biomarkers that only correlate with conversion from antibodies whose functional activity independently precedes and predicts tissue injury.
Show evidence (2 references)
PMID:20685079 SUPPORT Human Clinical
"However, it is presumed that autoreactive T cells, rather than antibodies, are the main effectors of adrenal gland destruction"
This supplies the adrenal example motivating the distinction.
PMID:23159534 SUPPORT Human Clinical
"Autoantibodies to the various endocrine and non-endocrine tissues not only offer a diagnostic clue to the autoimmune nature of diseases but also can be used to identify asymptomatic individuals who are at risk"
This supports diagnostic and predictive utility without claiming direct injury.
Does interferon-γ/JAK-STAT inhibition provide durable, safe, controlled benefit across APS-1 manifestations, and does the same effector program apply to polygenic adult APS types 2-4?
KNOWLEDGE GAP OPEN aps1_interferon_trial_and_cross_subtype_generalizability
Attached to
pathophysiology#APS-1 Interferon-γ–JAK-STAT Effector Program treatments#Ruxolitinib for Severe APS-1 Autoimmune Manifestations
Causal mouse perturbations and a five-patient human pilot are compelling but cannot define long-term safety, comparative efficacy, organ-specific response, or applicability beyond AIRE deficiency.
Proposed experiments
Controlled APS-1 interferon-pathway trial with adult APS comparator profiling
randomized mechanistic clinical trial Relation: this experiment is of type this experiment type This experiment is of type randomized mechanistic clinical trial.
exp_controlled_aps1_ifng_jak_trial
Randomize manifestation-defined APS-1 participants to interferon-γ or JAK pathway blockade versus control, with prespecified clinical endpoints, infection monitoring, tissue IFN-γ/pSTAT1/CXCL9 pharmacodynamics, and long-term follow-up. Profile the same pathway in untreated APS-2/3 cohorts without assuming treatment eligibility.
Decision criterion
Confirm clinically meaningful benefit with an on-target tissue response and acceptable safety, then determine whether adult APS shares the baseline pathway signature.
Show evidence (1 reference)
PMID:38810185 SUPPORT Human Clinical
"JAK inhibition with ruxolitinib in five patients showed promising results."
The small pilot size and qualified conclusion define the evidence gap.
Which APS-1 mechanisms and organ phenotypes are faithfully reproduced by the Aire-null mouse, and which human manifestations require rat, organoid, or patient-tissue models?
HUMAN MODEL MISMATCH OPEN aire_mouse_human_phenotype_mismatch
Attached to
pathophysiology#AIRE-Dependent Central Tolerance Failure animal_models#Aire-/- knockout mouse
Aire-null mice establish central-tolerance and interferon-effector biology, but the model incompletely reproduces human APECED's organ distribution and clinical phenotype. Translational conclusions should therefore be separated into conserved mechanism versus model-specific disease expression.
Proposed experiments
Cross-species AIRE-deficiency multiorgan immune atlas
cross-species single-cell and spatial profiling Relation: this experiment is of type this experiment type This experiment is of type cross-species single-cell and spatial profiling.
exp_aire_cross_species_multiorgan_atlas
Generate matched single-cell and spatial immune profiles from Aire-null mouse and rat target organs and available human APS-1 biopsies, with common antigen-specific T-cell, interferon, and tissue-injury readouts.
Decision criterion
Identify conserved cell states and causal pathways separately from species-specific organ tropism and manifestations.
Show evidence (1 reference)
PMID:33729987 SUPPORT Model Organism
"However, these murine models poorly recapitulate all phenotypic aspects of human APECED."
The review explicitly identifies incomplete human-phenotype fidelity of the mouse models.
Can a longitudinal adult APS type 2-4 cohort provide current natural-history, trial-readiness, and public multi-omic resources comparable to emerging APS-1 studies?
KNOWLEDGE GAP OPEN adult_aps_trials_and_public_omics_gap
Attached to
has_subtypes#Type 2 has_subtypes#Type 3 has_subtypes#Type 4 datasets#geo:GSE225460 datasets#geo:GSE243061
Exact registry and GEO audits on 2026-07-21 found active interventional work concentrated on APS-1 manifestations and the selected public transcriptomic datasets concentrated on APS-1. The one selected APS-2 registry is observational and had stale status verification. This limits cross-subtype mechanism comparison and adult trial design.
Proposed experiments
Longitudinal adult APS type 2-4 natural-history and multi-omic cohort
longitudinal multi-omic natural-history study Relation: this experiment is of type this experiment type This experiment is of type longitudinal multi-omic natural-history study.
exp_adult_aps_longitudinal_multiomic_cohort
Recruit well-phenotyped type 2-4 participants and at-risk relatives across centers; collect serial gland-function, autoantibody, antigen-specific T-cell, genotype, transcriptome, and outcome data under a public controlled-access data plan.
Decision criterion
Define reproducible molecular endotypes and prospective conversion markers that can support adult APS prevention or mechanism-directed trials.
Show evidence (2 references)
clinicaltrials:NCT05578105 SUPPORT Human Clinical
"In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan."
This is observational rather than an adult APS intervention trial.
PMID:38632993 SUPPORT Human Clinical
"We have used single cell transcriptomics to characterize regulatory T cells (Tregs) sorted directly from blood and from in vitro expanded Tregs in APS-1 patients compared to healthy controls."
The selected public single-cell resource is specifically APS-1, illustrating the subtype imbalance.
⚙

Pathophysiology

5
AIRE-Dependent Central Tolerance Failure
Mechanism confidence: Established
In APS-1, biallelic AIRE deficiency reduces thymic display of tissue-restricted self-antigens by medullary thymic epithelial cells. Failed negative selection permits self-reactive T cells to leave the thymus and seed a lifelong multiorgan autoimmune repertoire. This initiating lesion is specific to type 1 and is not generalized to adult polygenic types 2-4.
medullary thymic epithelial cell CL:0002365 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves medullary thymic epithelial cell (CL:0002365). CL:0002365 is a cell type from the Cell Ontology.
AIRE hgnc:360 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves AIRE (hgnc:360). hgnc:360 is a gene from the HUGO Gene Nomenclature Committee.
central T cell tolerance induction GO:0002512 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased central T cell tolerance induction (GO:0002512). GO:0002512 is a biological process from the Gene Ontology. ↓ DECREASED negative T cell selection GO:0043383 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased negative T cell selection (GO:0043383). GO:0043383 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Organ-Specific Autoreactive T-Cell Effector Injury Escaped self-reactive T cells infiltrate endocrine and non-endocrine target organs.
APS-1 Interferon-γ–JAK-STAT Effector Program In APS-1, AIRE deficiency permits the T-cell compartment that generates an excessive multiorgan interferon-γ response.
Show evidence (2 references)
PMID:12376594 SUPPORT Model Organism
"Aire-deficient thymic medullary epithelial cells showed a specific reduction in ectopic transcription of genes encoding peripheral antigens."
This establishes AIRE-dependent peripheral-antigen expression in medullary thymic epithelial cells.
PMID:38810185 SUPPORT Human Clinical
"In APS-1, self-reactive T cells escape thymic negative selection, infiltrate organs, and drive autoimmune injury."
This connects AIRE deficiency to failed negative selection and organ-infiltrating self-reactive T cells in APS-1.
Polygenic HLA and Immune-Regulatory Susceptibility
Mechanism confidence: Provisional
Adult autoimmune polyendocrinopathy, especially type 2, is associated with HLA class II and immune-regulatory susceptibility loci including HLA-DRB1, CTLA4, and PTPN22. These alleles alter the probability of organ-specific autoimmunity but neither define a single pathway nor cause the syndrome by themselves; environmental and other genetic factors remain necessary.
professional antigen presenting cell CL:0000145 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves professional antigen presenting cell (CL:0000145). CL:0000145 is a cell type from the Cell Ontology.
HLA-DRB1 hgnc:4948 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HLA-DRB1 (hgnc:4948). hgnc:4948 is a gene from the HUGO Gene Nomenclature Committee. CTLA4 hgnc:2505 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CTLA4 (hgnc:2505). hgnc:2505 is a gene from the HUGO Gene Nomenclature Committee. PTPN22 hgnc:9652 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTPN22 (hgnc:9652). hgnc:9652 is a gene from the HUGO Gene Nomenclature Committee.
antigen processing and presentation of peptide antigen via MHC class II GO:0002495 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal antigen processing and presentation of peptide antigen via MHC class II (GO:0002495). GO:0002495 is a biological process from the Gene Ontology. ⚠ ABNORMAL peripheral T cell tolerance induction GO:0002458 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased peripheral T cell tolerance induction (GO:0002458). GO:0002458 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Organ-Specific Autoreactive T-Cell Effector Injury Susceptibility loci lower the threshold for organ-specific cellular autoimmunity, but the intervening sequence and effect sizes vary by component disease.
Show evidence (2 references)
PMID:23159534 SUPPORT Human Clinical
"For PAS II, susceptibility genes are known which increase the risk for developing autoimmune disorders, but must not be causative. These are certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4) gene, and the protein tyrosine phosphatase non-receptor type 22 (PTPN22) genes"
This identifies the loci while explicitly limiting them to non-causative susceptibility.
PMID:23159534 SUPPORT Human Clinical
"Genetic susceptibility is necessary but not sufficient to produce the disorder. This is illustrated by the lack of 100% concordance of disease in identical twins."
This supports a multifactorial rather than deterministic genetic model.
Organ-Specific Autoreactive T-Cell Effector Injury
Mechanism confidence: Established
Autoreactive CD4 and CD8 T cells recognize tissue-restricted endocrine antigens and mediate lymphocytic gland injury. Direct human epitope evidence is strongest for 21-hydroxylase-reactive CD8 T cells in autoimmune adrenal insufficiency. Across the broader umbrella, autoantibodies track the same organ-specific loss of tolerance but should not be modeled generically as the destructive effector.
CD8-positive cytotoxic T cell CL:0000794 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8-positive cytotoxic T cell, annotated with CD8-positive, alpha-beta cytotoxic T cell (CL:0000794). CL:0000794 is a cell type from the Cell Ontology. CD4-positive helper T cell CL:0000492 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4-positive helper T cell (CL:0000492). CL:0000492 is a cell type from the Cell Ontology.
T cell mediated cytotoxicity GO:0001913 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased T cell mediated cytotoxicity (GO:0001913). GO:0001913 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Adrenal Insufficiency CD8 T-cell recognition of adrenal 21-hydroxylase accompanies autoimmune adrenal-cortex destruction.
Hashimoto Thyroiditis Thyroid-directed cellular autoimmunity can produce autoimmune thyroiditis in APS.
Type 1 Diabetes Mellitus Islet-directed cellular autoimmunity can eliminate insulin-producing beta-cell function.
Hypoparathyroidism Parathyroid-directed autoimmunity produces gland failure in APS-1.
Vitiligo Melanocyte-directed autoimmunity can produce vitiligo within the syndrome spectrum.
Atrophic Gastritis Gastric mucosal autoimmunity can progress to atrophic gastritis.
Alopecia Hair-follicle-directed autoimmunity can produce alopecia in APS.
Primary Hypogonadism Autoimmune gonadal injury can produce primary ovarian or testicular failure.
Show evidence (2 references)
PMID:20685079 SUPPORT Human Clinical
"However, it is presumed that autoreactive T cells, rather than antibodies, are the main effectors of adrenal gland destruction"
This directly corrects a generic autoantibody-mediated tissue-destruction model.
PMID:20685079 SUPPORT Human Clinical
"Blocking experiments identified IFNγ-producing cells as CD8 T lymphocytes, with two peptides frequently recognized in HLA-B8+ patients and a third one targeted in HLA-B35+ subjects."
Human epitope mapping identifies adrenal-antigen-reactive CD8 T cells.
APS-1 Interferon-γ–JAK-STAT Effector Program
Mechanism confidence: Provisional
APS-1 tissues show excessive T-cell-derived interferon-γ with downstream STAT1 phosphorylation and CXCL9 expression. Genetic loss of Ifng or JAK1/2 blockade in Aire-deficient mice prevented infiltration and tissue damage, and five patients improved during ruxolitinib treatment. This is a strong emerging APS-1 mechanism, not yet a syndrome-wide mechanism for types 2-4 or proof of established long-term clinical efficacy.
CD4-positive helper T cell CL:0000492 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4-positive helper T cell (CL:0000492). CL:0000492 is a cell type from the Cell Ontology. CD8-positive cytotoxic T cell CL:0000794 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8-positive cytotoxic T cell, annotated with CD8-positive, alpha-beta cytotoxic T cell (CL:0000794). CL:0000794 is a cell type from the Cell Ontology.
type II interferon-mediated signaling pathway GO:0060333 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased type II interferon-mediated signaling pathway (GO:0060333). GO:0060333 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Organ-Specific Autoreactive T-Cell Effector Injury Excessive interferon-γ–JAK-STAT signaling sustains organ infiltration and tissue injury in APS-1 models.
Show evidence (2 references)
PMID:38810185 SUPPORT Human Clinical
"Patients with APS-1 had enhanced interferon-γ responses in blood and in all examined autoimmunity-affected tissues."
This demonstrates a multiorgan interferon-γ signature in people with APS-1.
PMID:38810185 SUPPORT Model Organism
"Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice normalized interferon-γ responses and averted T-cell infiltration and damage in organs."
Genetic and pharmacologic perturbations establish interferon signaling as causal in the Aire-deficient mouse.
Neutralizing Th17-Cytokine Autoantibodies and Mucosal Antifungal Failure
Mechanism confidence: Established
In APS-1, neutralizing autoantibodies against IL-17A, IL-17F, and IL-22 can reduce Th17-associated mucosal antifungal defense. Unlike organ-specific endocrine autoantibodies, these anti-cytokine antibodies have a plausible functional role in chronic mucocutaneous candidiasis and are kept as a subtype-specific causal mechanism.
T-helper 17 cell CL:0000899 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T-helper 17 cell (CL:0000899). CL:0000899 is a cell type from the Cell Ontology.
cytokine-mediated signaling pathway GO:0019221 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cytokine-mediated signaling pathway (GO:0019221). GO:0019221 is a biological process from the Gene Ontology. ↓ DECREASED defense response to fungus GO:0050832 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased defense response to fungus (GO:0050832). GO:0050832 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Chronic Mucocutaneous Candidiasis Neutralization of IL-17F and IL-22 compromises mucosal defense against Candida.
Show evidence (1 reference)
PMID:20123959 SUPPORT Human Clinical
"Our multicenter survey revealed neutralizing autoantibodies against IL-17A (41%), IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients, especially those with CMC."
This large multicenter series identifies neutralizing Th17-cytokine autoantibodies in APS-1, enriched with CMC.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autoimmune Polyendocrinopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Digestive 1
Atrophic Gastritis HP:0002582 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atrophic gastritis (HP:0002582). HP:0002582 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35690244 SUPPORT Human Clinical
"APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis, pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis."
The review identifies gastritis and pernicious anemia among APS-1 manifestations.
Endocrine 5
Adrenal Insufficiency HP:0000846 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Adrenal insufficiency (HP:0000846). HP:0000846 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12050123 SUPPORT Human Clinical
"Autoimmune AD presented in four forms: as APS type 1 (13% of the patients), APS type 2 (41%), APS type 4 (5%), and isolated AD (41%)."
The cohort documents adrenal insufficiency across multiple traditional APS categories.
Hashimoto Thyroiditis HP:0000872 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hashimoto thyroiditis (HP:0000872). HP:0000872 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35690244 SUPPORT Human Clinical
"APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis, pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis."
This directly identifies autoimmune thyroiditis within APS-1.
PMID:33958142 SUPPORT Human Clinical
"SPA type 3 is characterized by autoimmune thyroid disease and other autoimmune disease, excluding Addison's disease and hypoparathyroidism"
This supports the broader autoimmune-thyroid component in type 3 without restricting it to Hashimoto disease.
Type 1 Diabetes Mellitus Type I diabetes mellitus HP:0100651 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Type 1 diabetes mellitus, annotated with Type I diabetes mellitus (HP:0100651). HP:0100651 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33958142 SUPPORT Human Clinical
"SPA type 2 presents with Addison's disease, type 1 diabetes, or autoimmune thyroid disease."
This establishes type 1 diabetes as an adult APS component.
Hypoparathyroidism HP:0000829 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoparathyroidism (HP:0000829). HP:0000829 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35690244 SUPPORT Human Clinical
"The classic triad of APS-1 includes chronic candidiasis of the skin and mucous membranes, adrenal insufficiency, and hypoparathyroidism."
This identifies hypoparathyroidism as a defining APS-1 manifestation.
Primary Hypogonadism HP:0000135 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Primary hypogonadism, annotated with Hypogonadism (HP:0000135). HP:0000135 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12050123 SUPPORT Human Clinical
"A varied prevalence of hypergonadotropic hypogonadism in patients with AD and value of steroid-producing cells autoantibodies reactive with steroid 17alpha-hydroxylase or P450 side-chain cleavage enzyme as markers of this disease has been discussed."
This supports autoimmune primary gonadal failure and explicitly cautions that prevalence varies.
Immune 1
Chronic Mucocutaneous Candidiasis HP:0002728 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic mucocutaneous candidiasis (HP:0002728). HP:0002728 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20123959 SUPPORT Human Clinical
"In autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED, or autoimmune polyendocrine syndrome 1), CMC is often the first sign"
This establishes CMC as an early APS-1 manifestation.
Integument 2
Vitiligo HP:0001045 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vitiligo (HP:0001045). HP:0001045 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35690244 SUPPORT Human Clinical
"APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis, pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis."
The review lists vitiligo within the APS-1 spectrum.
Alopecia HP:0001596 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Alopecia (HP:0001596). HP:0001596 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38810185 SUPPORT Human Clinical
"Ruxolitinib treatment of five patients with APS-1 led to decreased levels of T-cell–derived interferon-γ, normalized interferon-γ and CXCL9 levels, and remission of alopecia"
The pilot study directly documents alopecia and its remission during APS-1 treatment.
🧬

Genetic Associations

4
AIRE (Biallelic pathogenic variants cause APS-1)
Gene: AIRE hgnc:360 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AIRE (hgnc:360). hgnc:360 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Autosomal recessive inheritance
Show evidence (2 references)
PMID:35690244 SUPPORT Human Clinical
"APS-1 occurs because of mutations in the autoimmune regulator (AIRE) gene"
This supports the causal AIRE relationship for APS-1.
PMID:39292801 SUPPORT Human Clinical
"Through whole-genome sequencing, we identified a deep intronic AIRE variant (c.1504-818 G>A) cosegregating with the disease in all 17 patients."
This demonstrates a pathogenic deep intronic mechanism missed by conventional exon-focused testing.
HLA-DRB1 (HLA class II susceptibility in adult APS)
Gene: HLA-DRB1 hgnc:4948 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HLA-DRB1 (hgnc:4948). hgnc:4948 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR variant_origin: GERMLINE
Show evidence (1 reference)
PMID:23159534 SUPPORT Human Clinical
"A defect resides in one of the genes of the HLA locus which, in concert with other gene(s), results in susceptibility."
This supports a risk-factor rather than monogenic-causal relationship.
CTLA4 (Immune-regulatory susceptibility in adult APS)
Gene: CTLA4 hgnc:2505 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CTLA4 (hgnc:2505). hgnc:2505 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR variant_origin: GERMLINE
Show evidence (1 reference)
PMID:23159534 SUPPORT Human Clinical
"These are certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4) gene, and the protein tyrosine phosphatase non-receptor type 22 (PTPN22) genes on chromosomes 6, 2, and 1, respectively."
This identifies CTLA4 among type 2 susceptibility genes.
PTPN22 (Immune-regulatory susceptibility in adult APS)
Gene: PTPN22 hgnc:9652 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTPN22 (hgnc:9652). hgnc:9652 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR variant_origin: GERMLINE
Show evidence (1 reference)
PMID:23159534 SUPPORT Human Clinical
"These are certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4) gene, and the protein tyrosine phosphatase non-receptor type 22 (PTPN22) genes on chromosomes 6, 2, and 1, respectively."
This identifies PTPN22 among type 2 susceptibility genes.
💊

Medical Actions

4
Component-Specific Hormone Replacement
Category: Therapeutic Action: hormone modifying therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hormone modifying therapy, annotated with Hormone Therapy (NCIT:C15445). NCIT:C15445 is a clinical intervention from the NCI Thesaurus. Ontology label: Hormone Therapy NCIT:C15445
Replace hormones according to each confirmed gland failure, including glucocorticoid/mineralocorticoid, thyroid hormone, insulin, calcium/active vitamin D or parathyroid hormone strategies, and sex-steroid replacement as appropriate. Replacement treats the endocrine consequence; it does not restore immune tolerance or prevent every future component.
Target Phenotypes: Adrenal Insufficiency HP:0000846 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Adrenal Insufficiency (HP:0000846). HP:0000846 is a phenotype from the Human Phenotype Ontology. Hashimoto Thyroiditis HP:0000872 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hashimoto Thyroiditis (HP:0000872). HP:0000872 is a phenotype from the Human Phenotype Ontology. Type 1 Diabetes Mellitus HP:0100651 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Type 1 Diabetes Mellitus, annotated with Type I diabetes mellitus (HP:0100651). HP:0100651 is a phenotype from the Human Phenotype Ontology. Hypoparathyroidism HP:0000829 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypoparathyroidism (HP:0000829). HP:0000829 is a phenotype from the Human Phenotype Ontology. Primary Hypogonadism HP:0000135 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Primary Hypogonadism, annotated with Hypogonadism (HP:0000135). HP:0000135 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34790633 SUPPORT Human Clinical
"The goals of replacement treatment include the prevention of hypocalcemic crises"
The APS-1 management review supports consequence-directed replacement for hypoparathyroidism.
PMID:34790633 SUPPORT Human Clinical
"optimal pubertal development and growth in patients with hypogonadism"
This supports timely replacement for autoimmune gonadal failure.
Adrenal Stress Dosing and Emergency Preparedness
Category: Therapeutic Action: adrenal hormone replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is adrenal hormone replacement therapy, annotated with Hormone Replacement Therapy (NCIT:C15599). NCIT:C15599 is a clinical intervention from the NCI Thesaurus. Ontology label: Hormone Replacement Therapy NCIT:C15599
Patients with adrenal insufficiency require stress-dose education, access to injectable hydrocortisone, and medical-alert identification to reduce risk during febrile illness, procedures, vomiting, or other physiologic stress.
Target Phenotypes: Adrenal Insufficiency HP:0000846 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Adrenal Insufficiency (HP:0000846). HP:0000846 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34790633 SUPPORT Human Clinical
"access to parenteral hydrocortisone for acute stress dosing and"
This directly supports the emergency-preparedness action.
Antifungal Therapy for APS-1 Candidiasis
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: fluconazole CHEBI:46081 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses fluconazole (CHEBI:46081). CHEBI:46081 is a therapeutic agent from Chemical Entities of Biological Interest.
Treat active mucosal candidiasis in APS-1 with a topical or systemic antifungal selected according to site, severity, recurrence, culture, and susceptibility. Recurrent disease may require secondary prophylaxis; prolonged azole exposure requires attention to resistance and toxicity.
Target Phenotypes: Chronic Mucocutaneous Candidiasis HP:0002728 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Chronic Mucocutaneous Candidiasis (HP:0002728). HP:0002728 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34790633 SUPPORT Human Clinical
"Acute episodes of mucosal candidiasis respond well to induction therapy for four weeks"
This directly supports antifungal induction for active APS-1 mucosal candidiasis.
Ruxolitinib for Severe APS-1 Autoimmune Manifestations
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ruxolitinib CHEBI:66919 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ruxolitinib (CHEBI:66919). CHEBI:66919 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Ruxolitinib is an investigational, mechanism-directed option for selected severe APS-1 manifestations. The published human evidence is an uncontrolled five-patient pilot with promising multiorgan responses; efficacy, manifestation-specific benefit, infection risk, and long-term safety require prospective trial confirmation. It is not established therapy for adult types 2-4.
Mechanism Target:
INHIBITS APS-1 Interferon-γ–JAK-STAT Effector Program — JAK1/2 inhibition suppresses the excessive interferon-γ–STAT1 program identified in APS-1.
Show evidence (1 reference)
PMID:38810185 SUPPORT Model Organism
"Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice normalized interferon-γ responses and averted T-cell infiltration and damage in organs."
Pharmacologic and genetic perturbations support the targeted mechanism in the Aire-deficient mouse.
Target Phenotypes: Alopecia HP:0001596 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Alopecia (HP:0001596). HP:0001596 is a phenotype from the Human Phenotype Ontology. Atrophic Gastritis HP:0002582 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Atrophic Gastritis (HP:0002582). HP:0002582 is a phenotype from the Human Phenotype Ontology. Chronic Mucocutaneous Candidiasis HP:0002728 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Chronic Mucocutaneous Candidiasis (HP:0002728). HP:0002728 is a phenotype from the Human Phenotype Ontology. Hashimoto Thyroiditis HP:0000872 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hashimoto Thyroiditis (HP:0000872). HP:0000872 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38810185 SUPPORT Human Clinical
"Ruxolitinib treatment of five patients with APS-1 led to decreased levels of T-cell–derived interferon-γ, normalized interferon-γ and CXCL9 levels, and remission of alopecia, oral candidiasis, nail dystrophy, gastritis, enteritis, arthritis, Sjögren’s-like syndrome, urticaria, and thyroiditis."
This reports the five-patient mechanistic and clinical response signal.
PMID:38810185 SUPPORT Human Clinical
"JAK inhibition with ruxolitinib in five patients showed promising results."
The authors' conclusion is explicitly promising rather than definitive, supporting investigational framing.
🔬

Biochemical Markers

2
Organ-specific endocrine autoantibodies (PRESENT)
Pathograph Readouts
Correlates With Organ-Specific Autoreactive T-Cell Effector Injury Present Absent Diagnostic
Organ-specific autoantibodies support loss of tolerance to the corresponding tissue, but the antibody signal does not by itself establish functional failure.
Show evidence (1 reference)
PMID:23159534 SUPPORT Human Clinical
"Autoantibodies to the various endocrine and non-endocrine tissues not only offer a diagnostic clue to the autoimmune nature of diseases"
This directly supports their diagnostic biomarker role.
Predicts Organ-Specific Autoreactive T-Cell Effector Injury Present Absent Prognostic
In an at-risk patient, a component-specific autoantibody may precede clinical endocrine failure, with predictive value depending on antigen, age, titer, and functional testing.
Show evidence (1 reference)
PMID:12050123 SUPPORT Human Clinical
"In the course of natural history of autoimmune AD, the presence of adrenal cortex and/or steroid 21-hydroxylase autoantibodies identified patients at risk to develop AD."
This supports a predictive, not necessarily destructive, role for adrenal autoantibodies.
Show evidence (1 reference)
PMID:20685079 SUPPORT Human Clinical
"In autoimmune adrenal deficiency, autoantibodies target the 21-hydroxylase (21OH) protein. However, it is presumed that autoreactive T cells, rather than antibodies, are the main effectors of adrenal gland destruction"
This is the evidence boundary underlying biomarker rather than generic effector modeling.
APS-1 neutralizing Th17-cytokine autoantibodies (PRESENT)
Pathograph Readouts
Readout Of Neutralizing Th17-Cytokine Autoantibodies and Mucosal Antifungal Failure Present Absent Diagnostic
Neutralizing anti-IL-17F/IL-22 activity reports the APS-1 mucosal antifungal-failure mechanism, especially in a patient with CMC.
Show evidence (1 reference)
PMID:20123959 SUPPORT Human Clinical
"The autoantibodies preceded the CMC in all informative cases."
Temporal precedence supports a mechanistic biomarker interpretation.
Show evidence (1 reference)
PMID:20123959 SUPPORT Human Clinical
"Our multicenter survey revealed neutralizing autoantibodies against IL-17A (41%), IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients, especially those with CMC."
This supports the APS-1 anti-cytokine biomarker profile.
🔬

Diagnosis

4
Clinical assessment of component diseases
Establish the component endocrine diagnoses and determine whether at least two failures are autoimmune. Clinical pattern, age at onset, candidiasis, non-endocrine autoimmunity, treatment exposures, and family history guide classification; a traditional APS label is not a substitute for confirming each gland's functional state.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Results: Two autoimmune-induced endocrine failures support the umbrella diagnosis; the component pattern and genetic context determine the subtype assignment.
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"Autoimmune polyglandular diseases (APD) are defined as the presence of two autoimmune -induced endocrine failures."
This supplies the operational syndrome-level threshold.
Longitudinal endocrine functional testing
Measure hormone, electrolyte, glucose, and related gland-function markers according to the patient's current components and risks. Repeat testing is necessary because new endocrine failure can appear after a variable interval.
circulating hormone measurement NCIT:C74742 NCI Thesaurus (NCIT)
Results: Functional deficiency or stimulation-test failure establishes a component endocrinopathy; normal testing at one time point does not end surveillance.
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"This requires that patients at risk be regularly screened for subclinical endocrinopathies prior to clinical manifestation."
This supports repeated functional screening before overt disease.
Component-specific autoantibody testing
Measure organ-specific autoantibodies to support autoimmune attribution and risk stratification. Interpret results with symptoms and gland-function tests; antibody positivity alone is not equivalent to destructive endocrine failure.
antibody titer measurement NCIT:C25294 NCI Thesaurus (NCIT)
Results: A positive component-specific autoantibody supports autoimmune disease or future risk, with performance dependent on the antigen and clinical context.
Show evidence (1 reference)
PMID:33958142 SUPPORT Human Clinical
"the determination of autoantibodies can be useful to predict the risk of disease manifestation and to confirm the autoimmune disease in some cases."
This explicitly supports both predictive and confirmatory use with qualified certainty.
AIRE molecular genetic testing for suspected APS-1
Sequence AIRE when early onset, candidiasis, hypoparathyroidism, adrenal insufficiency, or other features suggest APS-1. If clinical suspicion remains high after conventional exon/splice testing, methods capable of detecting deep intronic or structural variants may be required.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Results: Biallelic pathogenic AIRE variants confirm APS-1; a negative conventional panel does not exclude deep intronic disease.
Show evidence (2 references)
PMID:35690244 SUPPORT Human Clinical
"Analysis of the AIRE gene is the main diagnostic method for early detection of APS-1"
This supports AIRE analysis in the APS-1 diagnostic pathway.
PMID:39292801 SUPPORT Human Clinical
"identified 17 patients (16%) from 14 kindreds lacking biallelic AIRE variants in exons or flanking intronic regions"
This demonstrates the limitation of conventional exon and flanking-intron testing in a clinically diagnosed cohort.
📈

Progression

2
First autoimmune endocrinopathy
A patient may initially have one clinically evident autoimmune endocrine failure and only later satisfy the umbrella definition when another gland is affected. The interval is variable and an incomplete presentation should not be assumed to be stable.
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"Regarding the time interval between manifestation of first and further endocrinopathies, regular and long-term follow-up is warranted."
The review explicitly describes temporal separation between the first and subsequent endocrinopathies.
Long-term accumulation and surveillance
Additional endocrine or non-endocrine autoimmune manifestations may emerge over prolonged follow-up. Surveillance is therefore longitudinal and tailored to subtype, existing component disease, symptoms, and family risk.
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"This requires that patients at risk be regularly screened for subclinical endocrinopathies prior to clinical manifestation."
This supports surveillance before another component becomes clinically overt.
⚖️

Clinical Burden

Variable
Burden ranges from controlled hormone deficiencies to acute adrenal crisis, diabetic ketoacidosis, hypocalcemic emergencies, chronic infection, and multiorgan autoimmunity. Lifelong replacement, surveillance, and coordination across specialties are common, and psychosocial burden extends to affected families. The broad umbrella prevents a single frequency or severity estimate from representing every subtype.
Show evidence (2 references)
PMID:31606344 SUPPORT Human Clinical
"With respect to the significant morbidity and potential mortality of APD, the diagnostic objective is to detect APD at an early stage"
This directly supports clinically important morbidity and potential mortality.
PMID:31606344 SUPPORT Human Clinical
"Quality of life and psychosocial status are poor in APD patients and involved relatives."
This supports patient and family quality-of-life burden.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Autoimmune Polyendocrinopathy:

IPEX syndrome MONDO:0010580
Overlapping Features IPEX can present in infancy with systemic autoimmunity, enteropathy, eczema, and endocrine disease, especially type 1 diabetes. Male sex, severe early enteropathy/dermatitis, regulatory-T-cell abnormalities, and a hemizygous FOXP3 variant distinguish it from traditional APS-1 or adult APS.
Distinguishing Features
  • Usually begins in the first year of life in an affected male.
  • Enteropathy and eczematous dermatitis accompany endocrinopathy.
  • A hemizygous pathogenic FOXP3 variant establishes the X-linked diagnosis.
Show evidence (1 reference)
PMID:20301297 SUPPORT Human Clinical
"IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome is characterized by systemic autoimmunity, typically beginning in the first year of life, which includes the triad of enteropathy (manifesting as malabsorption and watery diarrhea), endocrinopathy (most commonly type..."
This defines the early clinical pattern that distinguishes IPEX.
Multiple endocrine neoplasia type 2 MONDO:0019003
Overlapping Features MEN2 produces multiple endocrine abnormalities through neoplasia rather than multiglandular autoimmunity. Medullary thyroid carcinoma and pheochromocytoma, autosomal dominant inheritance, and a pathogenic RET variant favor MEN2.
Distinguishing Features
  • Endocrine tumors rather than autoimmune gland failure dominate.
  • Medullary thyroid carcinoma with pheochromocytoma is characteristic.
  • Pathogenic RET variants confer autosomal dominant disease.
Show evidence (1 reference)
PMID:11786689 SUPPORT Human Clinical
"MEN2 is characterized by medullary thyroid carcinoma (MTC) in association with phaeochromocytoma."
This states the neoplastic combination separating MEN2 from autoimmune polyendocrinopathy.
Immune checkpoint inhibitor-induced APS-2-like endocrinopathy
Overlapping Features Cancer immunotherapy can produce two or more immune-related endocrine failures that resemble APS-2. The temporal relationship to checkpoint inhibition and its acquired adverse-event context distinguish this from spontaneous familial or polygenic APS, while the same emergencies still require prompt recognition.
Distinguishing Features
  • Begins during or after CTLA-4, PD-1, or PD-L1 checkpoint-inhibitor exposure.
  • Is an acquired immune-related adverse event rather than an inherited syndrome.
  • Diabetic ketoacidosis or adrenal crisis may be the presenting emergency.
Show evidence (1 reference)
PMID:32905579 SUPPORT Human Clinical
"Here, we provide an overview of all published and reported cases (n = 30) of ICPis-induced APS-2."
This establishes a documented acquired APS-2-like treatment complication.
Isolated autoimmune endocrinopathy
Overlapping Features A single autoimmune endocrine disease does not yet meet the umbrella definition. It may remain isolated or represent an incomplete stage before a second component appears, so longitudinal surveillance is more appropriate than premature syndrome assignment.
Distinguishing Features
  • Only one autoimmune-induced endocrine failure is currently established.
  • A second gland must be confirmed before the umbrella definition is met.
Show evidence (1 reference)
PMID:31606344 SUPPORT Human Clinical
"Autoimmune polyglandular diseases (APD) are defined as the presence of two autoimmune -induced endocrine failures."
The two-failure definition distinguishes isolated disease from the umbrella syndrome.
📊

Related Datasets

3
The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1 geo:GSE225460
Human bulk RNA-sequencing dataset of oral mucosal biopsies from people with APECED and healthy donors, including a pre/post-ruxolitinib series. It is directly relevant to the tissue interferon-γ/CXCL9 mechanism but is small and APS-1-specific.
human BULK RNA SEQ n=8
oral mucosal biopsy UBERON:0003729 Uberon multi-species anatomy ontology (UBERON) Relation: this dataset samples this sample type This dataset samples oral mucosal biopsy, annotated with mouth mucosa (UBERON:0003729). UBERON:0003729 is a sample type from the Uberon multi-species anatomy ontology.
Conditions: APECED oral mucosa Healthy donor oral mucosa Pre/post-ruxolitinib APS-1 tissue series
PMID:38810185
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225460
Show evidence (1 reference)
PMID:38810185 SUPPORT Human Clinical
"Patients with APS-1 had enhanced interferon-γ responses in blood and in all examined autoimmunity-affected tissues."
The associated publication supports transcriptomic interrogation of affected human tissues.
Tregs in autoimmune polyendocrine syndrome type I geo:GSE243061
Single-cell transcriptomic study of regulatory T cells sorted from peripheral blood in four APS-1 participants and four healthy controls, with ex-vivo expansion analyses. GEO notes that raw patient data are withheld for privacy, which limits unrestricted reanalysis.
human SINGLE CELL RNA SEQ n=8
peripheral blood regulatory T cells CL:0000815 Cell Ontology (CL) Relation: this dataset samples this sample type This dataset samples peripheral blood regulatory T cells, annotated with regulatory T cell (CL:0000815). CL:0000815 is a sample type from the Cell Ontology.
Conditions: APS-1 Healthy control
PMID:38632993
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243061
Show evidence (1 reference)
PMID:38632993 SUPPORT Human Clinical
"We have used single cell transcriptomics to characterize regulatory T cells (Tregs) sorted directly from blood and from in vitro expanded Tregs in APS-1 patients compared to healthy controls."
The publication directly describes the dataset's cell population, assay, and comparison.
A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion geo:GSE254003
Bulk RNA-sequencing of human TEC4D6 thymic epithelial cells transfected with wild-type AIRE, pseudoexon-containing mutant AIRE, or GFP control. This is a mechanistic cell-line dataset rather than patient tissue and should not be used to estimate clinical expression frequencies.
human BULK RNA SEQ n=12
TEC4D6 thymic epithelial cell line CL:0002293 Cell Ontology (CL) Relation: this dataset samples this sample type This dataset samples TEC4D6 thymic epithelial cell line, annotated with epithelial cell of thymus (CL:0002293). CL:0002293 is a sample type from the Cell Ontology.
Conditions: Wild-type AIRE transfection Deep-intronic-variant AIRE transfection GFP control transfection
PMID:39292801
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254003
Show evidence (1 reference)
PMID:39292801 SUPPORT In Vitro
"Through protein modeling and transcriptomic analyses of AIRE-transfected human embryonic kidney 293 and thymic epithelial cell 4D6 cells, we showed that this variant alters the carboxyl terminus of the AIRE protein, abrogating its function."
The publication identifies the cell systems and transcriptomic purpose represented by the GEO series.
🔬

Clinical Trials

4
NCT05398809 PHASE_II RECRUITING
Recruiting open-label phase 2 study of oral ruxolitinib for severe alopecia areata in people aged 12-65 years with APECED. The registry listed an estimated enrollment of 70 and status verification in June 2026 at the 2026-07-21 audit. The endpoint is manifestation-specific hair regrowth, not proof of syndrome-wide disease modification.
Show evidence (1 reference)
clinicaltrials:NCT05398809 SUPPORT Human Clinical
"To see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body."
The registry states the ruxolitinib objective and APECED-associated alopecia population.
NCT07202598 PHASE_II RECRUITING
Recruiting randomized stepped-wedge phase 2 study of the interferon-γ antibody emapalumab for APECED enteritis. The registry listed an estimated enrollment of 10 and status verification in December 2025 at the 2026-07-21 audit. It tests one severe APS-1 manifestation rather than adult APS types.
Show evidence (1 reference)
clinicaltrials:NCT07202598 SUPPORT Human Clinical
"To test a drug (emapalumab) in people with enteritis caused by APECED."
The registry states the intervention, disease, and manifestation-specific objective.
NCT05578105 NOT_APPLICABLE RECRUITING
Observational Taiwan study of APS type 2 epidemiology, clinical characteristics, and genetic variation, with estimated enrollment of 650. The recruiting status had last been verified in October 2022 at the 2026-07-21 audit, so operational currency is uncertain and no intervention efficacy can be inferred.
Show evidence (1 reference)
clinicaltrials:NCT05578105 SUPPORT Human Clinical
"In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan."
The registry defines this as an observational adult APS-2 study.
NCT05716607 NOT_APPLICABLE WITHDRAWN
Randomized crossover study planned to examine glycemic variability in people treated with both insulin and hydrocortisone. The registry was withdrawn before enrollment with an actual enrollment of zero at the 2026-07-21 audit; it therefore supplies no outcome evidence.
Show evidence (1 reference)
clinicaltrials:NCT05716607 SUPPORT Human Clinical
"The aim of INS.CORT trial is"
The registry documents the planned combined insulin/hydrocortisone study; its withdrawn status precludes efficacy inference.
🐁

Animal Models

1
Aire-/- knockout mouse mouse Germline knockout model of APS-1 central-tolerance failure
Aire-null mice develop multiorgan lymphocytic infiltrates, circulating autoantibodies, altered peripheral T-cell responses, and infertility. The model is mechanistically informative for AIRE-dependent tolerance and interferon perturbation but does not reproduce the entire human APECED phenotype.
Multiorgan lymphocytic infiltration Circulating autoantibodies Infertility
Species
mouse
Genotype
Aire-/- knockout mouse
Genes
AIRE hgnc:360 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns AIRE (hgnc:360). hgnc:360 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:11854172 SUPPORT Model Organism
"The Aire-/- mice develop normally; however, autoimmune features of APECED in Aire-/- mice are evident, including multiorgan lymphocytic infiltration, circulating autoantibodies and infertility."
This directly identifies the principal phenotypes of the knockout model.
PMID:38810185 SUPPORT Model Organism
"Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice normalized interferon-γ responses and averted T-cell infiltration and damage in organs."
This establishes the model's use for causal interferon-pathway perturbation.
{ }

Source YAML

click to show 
name: Autoimmune Polyendocrinopathy
creation_date: "2026-05-12T18:00:00Z"
category: Autoimmune
synonyms:
- Autoimmune polyendocrine syndrome
- APS
- Polyglandular autoimmune syndrome
- Autoimmune polyglandular disease
description: >-
  Autoimmune polyendocrinopathy is an umbrella for syndromes in which at least
  two endocrine glands develop autoimmune failure, often with non-endocrine
  autoimmunity. This entry retains the traditional MONDO-linked types 1-4 while
  making their unequal biology explicit: type 1 (APS-1/APECED) is a monogenic
  AIRE-deficiency disorder, whereas adult types 2-4 are clinical combinations
  with polygenic immune susceptibility. Organ-specific autoantibodies are
  clinically useful diagnostic and predictive markers, but autoreactive T cells
  rather than the antibodies are considered the principal tissue-damaging
  effectors in well-studied endocrine components. Detailed APS-1 phenotyping is
  curated separately in Autoimmune_Polyendocrine_Syndrome_Type_1.yaml; this file
  emphasizes shared mechanisms, classification boundaries, surveillance, and
  cross-subtype evidence.
disease_term:
  preferred_term: autoimmune polyendocrinopathy
  term:
    id: MONDO:0017278
    label: autoimmune polyendocrinopathy
parents:
- Autoimmune disorder of endocrine system
- Polyendocrinopathy
definitions:
- name: Clinical umbrella definition
  definition_type: CASE_DEFINITION
  description: >-
    Autoimmune polyglandular disease is defined clinically by two
    autoimmune-induced endocrine failures. Individual type definitions then
    depend on the component diseases and, for APS-1, the monogenic context.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune polyglandular diseases (APD) are defined as the presence of two
      autoimmune -induced endocrine failures.
    explanation: This review states the disease-level clinical definition used for the umbrella entry.
has_subtypes:
- name: Type 1
  display_name: Type 1 (APS-1/APECED)
  description: >-
    Monogenic, usually childhood-onset autoimmune polyendocrinopathy caused by
    biallelic AIRE deficiency. Chronic mucocutaneous candidiasis,
    hypoparathyroidism, and adrenal insufficiency form the classic triad. A
    separate disease entry contains the detailed APECED phenotype and management
    model; here APS-1 is retained to connect it to the broader umbrella.
  subtype_term:
    preferred_term: autoimmune polyendocrine syndrome type 1
    term:
      id: MONDO:0009411
      label: autoimmune polyendocrine syndrome type 1
  evidence:
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      APS type 1 presents with hypoparathyroidism, mucocutaneous candidiasis and
      Addison's disease. It is caused by AutoImmune Regulator (AIRE) gene mutation.
    explanation: The review defines the classic APS-1 component diseases and AIRE basis.
- name: Type 2
  display_name: Type 2 (Schmidt syndrome)
  description: >-
    Adult/polygenic syndrome centered on primary adrenal insufficiency with
    autoimmune thyroid disease and/or type 1 diabetes. HLA and immune-regulatory
    alleles modify risk but are not sufficient causes.
  subtype_term:
    preferred_term: autoimmune polyendocrinopathy type 2
    term:
      id: MONDO:0010012
      label: autoimmune polyendocrinopathy type 2
  evidence:
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SPA type 2 presents with Addison's disease, type 1 diabetes, or autoimmune
      thyroid disease. Multiple genes have been implicated, including those of
      the class II major histocompatibility complex.
    explanation: This supports the component-disease and polygenic framing of type 2.
- name: Type 3
  display_name: Type 3
  description: >-
    Autoimmune thyroid disease with another autoimmune disorder, excluding
    Addison disease and hypoparathyroidism under the traditional classification.
    It is a clinical-combination category rather than a single established
    molecular etiology.
  subtype_term:
    preferred_term: autoimmune polyendocrinopathy type 3
    term:
      id: MONDO:0016422
      label: autoimmune polyendocrinopathy type 3
  evidence:
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SPA type 3 is characterized by autoimmune thyroid disease and other
      autoimmune disease, excluding Addison's disease and hypoparathyroidism, 4
      genes have been implicated and confer susceptibility.
    explanation: This states the traditional inclusion and exclusion boundary for type 3.
- name: Type 4
  display_name: Type 4
  description: >-
    A residual traditional category for combinations of autoimmune endocrine
    disease not assigned to types 1-3. Its boundaries depend on the classification
    system and should not be interpreted as a unified mechanism.
  subtype_term:
    preferred_term: autoimmune polyendocrinopathy type 4
    term:
      id: MONDO:0016423
      label: autoimmune polyendocrinopathy type 4
  evidence:
  - reference: PMID:12050123
    reference_title: "Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune AD presented in four forms: as APS type 1 (13% of the patients),
      APS type 2 (41%), APS type 4 (5%), and isolated AD (41%).
    explanation: This clinical series documents use of the type 4 category without implying a distinct molecular cause.
progression:
- phase: First autoimmune endocrinopathy
  notes: >-
    A patient may initially have one clinically evident autoimmune endocrine
    failure and only later satisfy the umbrella definition when another gland is
    affected. The interval is variable and an incomplete presentation should not
    be assumed to be stable.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Regarding the time interval between manifestation of first and further
      endocrinopathies, regular and long-term follow-up is warranted.
    explanation: The review explicitly describes temporal separation between the first and subsequent endocrinopathies.
- phase: Long-term accumulation and surveillance
  notes: >-
    Additional endocrine or non-endocrine autoimmune manifestations may emerge
    over prolonged follow-up. Surveillance is therefore longitudinal and tailored
    to subtype, existing component disease, symptoms, and family risk.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This requires that patients at risk be regularly screened for subclinical
      endocrinopathies prior to clinical manifestation.
    explanation: This supports surveillance before another component becomes clinically overt.
clinical_burden:
  burden_level: VARIABLE
  rationale: >-
    Burden ranges from controlled hormone deficiencies to acute adrenal crisis,
    diabetic ketoacidosis, hypocalcemic emergencies, chronic infection, and
    multiorgan autoimmunity. Lifelong replacement, surveillance, and coordination
    across specialties are common, and psychosocial burden extends to affected
    families. The broad umbrella prevents a single frequency or severity estimate
    from representing every subtype.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With respect to the significant morbidity and potential mortality of APD,
      the diagnostic objective is to detect APD at an early stage
    explanation: This directly supports clinically important morbidity and potential mortality.
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Quality of life and psychosocial status are poor in APD patients and involved relatives.
    explanation: This supports patient and family quality-of-life burden.
pathophysiology:
- name: AIRE-Dependent Central Tolerance Failure
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    In APS-1, biallelic AIRE deficiency reduces thymic display of
    tissue-restricted self-antigens by medullary thymic epithelial cells. Failed
    negative selection permits self-reactive T cells to leave the thymus and
    seed a lifelong multiorgan autoimmune repertoire. This initiating lesion is
    specific to type 1 and is not generalized to adult polygenic types 2-4.
  genes:
  - preferred_term: AIRE
    term:
      id: hgnc:360
      label: AIRE
  cell_types:
  - preferred_term: medullary thymic epithelial cell
    term:
      id: CL:0002365
      label: medullary thymic epithelial cell
  biological_processes:
  - preferred_term: central T cell tolerance induction
    term:
      id: GO:0002512
      label: central T cell tolerance induction
    modifier: DECREASED
  - preferred_term: negative T cell selection
    term:
      id: GO:0043383
      label: negative T cell selection
    modifier: DECREASED
  evidence:
  - reference: PMID:12376594
    reference_title: Projection of an immunological self shadow within the thymus by the aire protein.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Aire-deficient thymic medullary epithelial cells showed a specific
      reduction in ectopic transcription of genes encoding peripheral antigens.
    explanation: This establishes AIRE-dependent peripheral-antigen expression in medullary thymic epithelial cells.
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In APS-1, self-reactive T cells escape thymic negative selection,
      infiltrate organs, and drive autoimmune injury.
    explanation: This connects AIRE deficiency to failed negative selection and organ-infiltrating self-reactive T cells in APS-1.
  downstream:
  - target: Organ-Specific Autoreactive T-Cell Effector Injury
    causal_link_type: DIRECT
    description: Escaped self-reactive T cells infiltrate endocrine and non-endocrine target organs.
    evidence:
    - reference: PMID:38810185
      reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In APS-1, self-reactive T cells escape thymic negative selection,
        infiltrate organs, and drive autoimmune injury.
      explanation: The study states the source-to-effector sequence represented by this edge.
  - target: APS-1 Interferon-γ–JAK-STAT Effector Program
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Escape and organ recruitment of AIRE-dependent self-reactive T cells
    description: >-
      In APS-1, AIRE deficiency permits the T-cell compartment that generates an
      excessive multiorgan interferon-γ response.
    evidence:
    - reference: PMID:38810185
      reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Our findings indicate that APS-1, which is caused by AIRE deficiency, is
        characterized by excessive, multiorgan interferon-γ–mediated responses.
      explanation: This supports an AIRE-deficiency-to-interferon program mediated by the escaped T-cell repertoire.
- name: Polygenic HLA and Immune-Regulatory Susceptibility
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    Adult autoimmune polyendocrinopathy, especially type 2, is associated with
    HLA class II and immune-regulatory susceptibility loci including HLA-DRB1,
    CTLA4, and PTPN22. These alleles alter the probability of organ-specific
    autoimmunity but neither define a single pathway nor cause the syndrome by
    themselves; environmental and other genetic factors remain necessary.
  genes:
  - preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  - preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  - preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  cell_types:
  - preferred_term: professional antigen presenting cell
    term:
      id: CL:0000145
      label: professional antigen presenting cell
  biological_processes:
  - preferred_term: antigen processing and presentation of peptide antigen via MHC class II
    term:
      id: GO:0002495
      label: antigen processing and presentation of peptide antigen via MHC class II
    modifier: ABNORMAL
  - preferred_term: peripheral T cell tolerance induction
    term:
      id: GO:0002458
      label: peripheral T cell tolerance induction
    modifier: DECREASED
  evidence:
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For PAS II, susceptibility genes are known which increase the risk for
      developing autoimmune disorders, but must not be causative. These are
      certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4) gene, and
      the protein tyrosine phosphatase non-receptor type 22 (PTPN22) genes
    explanation: This identifies the loci while explicitly limiting them to non-causative susceptibility.
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic susceptibility is necessary but not sufficient to produce the
      disorder. This is illustrated by the lack of 100% concordance of disease
      in identical twins.
    explanation: This supports a multifactorial rather than deterministic genetic model.
  downstream:
  - target: Organ-Specific Autoreactive T-Cell Effector Injury
    causal_link_type: UNKNOWN
    description: >-
      Susceptibility loci lower the threshold for organ-specific cellular
      autoimmunity, but the intervening sequence and effect sizes vary by
      component disease.
    evidence:
    - reference: PMID:23159534
      reference_title: Polyglandular autoimmune syndrome type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The nature of PAS has been based on the presence of lymphocyte
        infiltration in the affected gland, organ-specific antibodies in the
        serum, cellular immune defects and an association with the human
        leucocyte antigen (HLA) DR/DQ genes or immune response genes.
      explanation: This associates HLA/immune-response genes with glandular lymphocyte infiltration but does not resolve a uniform causal chain.
- name: Organ-Specific Autoreactive T-Cell Effector Injury
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Autoreactive CD4 and CD8 T cells recognize tissue-restricted endocrine
    antigens and mediate lymphocytic gland injury. Direct human epitope evidence
    is strongest for 21-hydroxylase-reactive CD8 T cells in autoimmune adrenal
    insufficiency. Across the broader umbrella, autoantibodies track the same
    organ-specific loss of tolerance but should not be modeled generically as
    the destructive effector.
  cell_types:
  - preferred_term: CD8-positive cytotoxic T cell
    term:
      id: CL:0000794
      label: CD8-positive, alpha-beta cytotoxic T cell
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: T cell mediated cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
    modifier: INCREASED
  evidence:
  - reference: PMID:20685079
    reference_title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, it is presumed that autoreactive T cells, rather than antibodies,
      are the main effectors of adrenal gland destruction
    explanation: This directly corrects a generic autoantibody-mediated tissue-destruction model.
  - reference: PMID:20685079
    reference_title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blocking experiments identified IFNγ-producing cells as CD8 T lymphocytes,
      with two peptides frequently recognized in HLA-B8+ patients and a third
      one targeted in HLA-B35+ subjects.
    explanation: Human epitope mapping identifies adrenal-antigen-reactive CD8 T cells.
  downstream:
  - target: Adrenal Insufficiency
    causal_link_type: DIRECT
    description: CD8 T-cell recognition of adrenal 21-hydroxylase accompanies autoimmune adrenal-cortex destruction.
    evidence:
    - reference: PMID:20685079
      reference_title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        circulating EPLARLEL-specific CD8 T cells were detected at significant
        frequencies in HLA-B8+ patients but not in controls by HLA tetramer staining.
      explanation: Disease-specific circulating CD8 T cells recognize a 21-hydroxylase epitope in affected patients.
  - target: Hashimoto Thyroiditis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Thyroid-directed cellular autoimmunity can produce autoimmune thyroiditis in APS.
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
        thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
        pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
      explanation: The review supports thyroiditis as an APS manifestation; the exact effector sequence is not resolved for every subtype.
  - target: Type 1 Diabetes Mellitus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Islet-directed cellular autoimmunity can eliminate insulin-producing beta-cell function.
    evidence:
    - reference: PMID:33958142
      reference_title: Autoinmune polyendocrinopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        SPA type 2 presents with Addison's disease, type 1 diabetes, or autoimmune thyroid disease.
      explanation: This establishes type 1 diabetes within adult APS, while the shared T-cell edge remains a mechanistic synthesis.
  - target: Hypoparathyroidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Parathyroid-directed autoimmunity produces gland failure in APS-1.
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The classic triad of APS-1 includes chronic candidiasis of the skin and
        mucous membranes, adrenal insufficiency, and hypoparathyroidism.
      explanation: The review establishes hypoparathyroidism as a defining APS-1 component while detailed effector intermediates remain incompletely resolved.
  - target: Vitiligo
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Melanocyte-directed autoimmunity can produce vitiligo within the syndrome spectrum.
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
        thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
        pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
      explanation: This lists vitiligo within APS-1; the cellular edge is conservatively indirect.
  - target: Atrophic Gastritis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Gastric mucosal autoimmunity can progress to atrophic gastritis.
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
        thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
        pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
      explanation: This identifies gastritis within the APS-1 spectrum but does not prove each intervening cellular step.
  - target: Alopecia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hair-follicle-directed autoimmunity can produce alopecia in APS.
    evidence:
    - reference: PMID:38810185
      reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Ruxolitinib treatment of five patients with APS-1 led to decreased levels
        of T-cell–derived interferon-γ, normalized interferon-γ and CXCL9 levels,
        and remission of alopecia
      explanation: Coupled immune-response suppression and alopecia remission support, but do not by themselves fully resolve, the cellular causal chain.
  - target: Primary Hypogonadism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Autoimmune gonadal injury can produce primary ovarian or testicular failure.
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
        thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
        pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
      explanation: The review identifies gonadal failure in APS-1 while the tissue-specific effector chain remains incompletely mapped.
- name: APS-1 Interferon-γ–JAK-STAT Effector Program
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    APS-1 tissues show excessive T-cell-derived interferon-γ with downstream
    STAT1 phosphorylation and CXCL9 expression. Genetic loss of Ifng or JAK1/2
    blockade in Aire-deficient mice prevented infiltration and tissue damage,
    and five patients improved during ruxolitinib treatment. This is a strong
    emerging APS-1 mechanism, not yet a syndrome-wide mechanism for types 2-4
    or proof of established long-term clinical efficacy.
  cell_types:
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  - preferred_term: CD8-positive cytotoxic T cell
    term:
      id: CL:0000794
      label: CD8-positive, alpha-beta cytotoxic T cell
  biological_processes:
  - preferred_term: type II interferon-mediated signaling pathway
    term:
      id: GO:0060333
      label: type II interferon-mediated signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with APS-1 had enhanced interferon-γ responses in blood and in all
      examined autoimmunity-affected tissues.
    explanation: This demonstrates a multiorgan interferon-γ signature in people with APS-1.
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice
      normalized interferon-γ responses and averted T-cell infiltration and
      damage in organs.
    explanation: Genetic and pharmacologic perturbations establish interferon signaling as causal in the Aire-deficient mouse.
  downstream:
  - target: Organ-Specific Autoreactive T-Cell Effector Injury
    causal_link_type: DIRECT
    description: Excessive interferon-γ–JAK-STAT signaling sustains organ infiltration and tissue injury in APS-1 models.
    evidence:
    - reference: PMID:38810185
      reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice
        normalized interferon-γ responses and averted T-cell infiltration and
        damage in organs.
      explanation: Dual perturbation supports the interferon-program-to-tissue-injury edge in the model.
- name: Neutralizing Th17-Cytokine Autoantibodies and Mucosal Antifungal Failure
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    In APS-1, neutralizing autoantibodies against IL-17A, IL-17F, and IL-22 can
    reduce Th17-associated mucosal antifungal defense. Unlike organ-specific
    endocrine autoantibodies, these anti-cytokine antibodies have a plausible
    functional role in chronic mucocutaneous candidiasis and are kept as a
    subtype-specific causal mechanism.
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
    modifier: DECREASED
  - preferred_term: defense response to fungus
    term:
      id: GO:0050832
      label: defense response to fungus
    modifier: DECREASED
  evidence:
  - reference: PMID:20123959
    reference_title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our multicenter survey revealed neutralizing autoantibodies against IL-17A
      (41%), IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients,
      especially those with CMC.
    explanation: This large multicenter series identifies neutralizing Th17-cytokine autoantibodies in APS-1, enriched with CMC.
  downstream:
  - target: Chronic Mucocutaneous Candidiasis
    causal_link_type: DIRECT
    description: Neutralization of IL-17F and IL-22 compromises mucosal defense against Candida.
    evidence:
    - reference: PMID:20123959
      reference_title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We conclude that IL-22 and IL-17F are key natural defenders against CMC
        and that the immunodeficiency underlying CMC in both patient groups has
        an autoimmune basis.
      explanation: This directly supports loss of Th17-cytokine function as the autoimmune basis of CMC.
phenotypes:
- name: Adrenal Insufficiency
  category: Endocrine
  description: >-
    Autoimmune primary adrenal-cortex failure is a defining component of type 2
    and occurs in APS-1 and some residual type 4 combinations. Clinical urgency
    derives from the risk of adrenal crisis.
  phenotype_term:
    preferred_term: Adrenal insufficiency
    term:
      id: HP:0000846
      label: Adrenal insufficiency
  evidence:
  - reference: PMID:12050123
    reference_title: "Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune AD presented in four forms: as APS type 1 (13% of the patients),
      APS type 2 (41%), APS type 4 (5%), and isolated AD (41%).
    explanation: The cohort documents adrenal insufficiency across multiple traditional APS categories.
- name: Hashimoto Thyroiditis
  category: Endocrine
  description: >-
    Autoimmune thyroiditis with hypothyroidism is a common thyroid component of
    adult APS and can occur in APS-1. Autoimmune thyroid disease, rather than
    Hashimoto thyroiditis alone, defines the traditional types 2 and 3.
  phenotype_term:
    preferred_term: Hashimoto thyroiditis
    term:
      id: HP:0000872
      label: Hashimoto thyroiditis
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
      thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
      pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
    explanation: This directly identifies autoimmune thyroiditis within APS-1.
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SPA type 3 is characterized by autoimmune thyroid disease and other
      autoimmune disease, excluding Addison's disease and hypoparathyroidism
    explanation: This supports the broader autoimmune-thyroid component in type 3 without restricting it to Hashimoto disease.
- name: Type 1 Diabetes Mellitus
  category: Endocrine
  description: >-
    Immune-mediated beta-cell loss and insulin deficiency can participate in
    types 2 and 3 and occurs in some people with APS-1.
  phenotype_term:
    preferred_term: Type 1 diabetes mellitus
    term:
      id: HP:0100651
      label: Type I diabetes mellitus
  evidence:
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SPA type 2 presents with Addison's disease, type 1 diabetes, or autoimmune thyroid disease.
    explanation: This establishes type 1 diabetes as an adult APS component.
- name: Hypoparathyroidism
  category: Endocrine
  description: >-
    Hypoparathyroidism is one component of the classic APS-1 triad. Its presence
    is an exclusion in the traditional type 3 definition, so it should not be
    treated as a universal umbrella feature.
  phenotype_term:
    preferred_term: Hypoparathyroidism
    term:
      id: HP:0000829
      label: Hypoparathyroidism
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The classic triad of APS-1 includes chronic candidiasis of the skin and
      mucous membranes, adrenal insufficiency, and hypoparathyroidism.
    explanation: This identifies hypoparathyroidism as a defining APS-1 manifestation.
- name: Chronic Mucocutaneous Candidiasis
  category: Immunologic
  description: >-
    Persistent or recurrent Candida infection of mucosa, skin, or nails is a
    hallmark of APS-1 and is linked to impaired Th17-cytokine activity. It is not
    a defining manifestation of adult types 2-4.
  phenotype_term:
    preferred_term: Chronic mucocutaneous candidiasis
    term:
      id: HP:0002728
      label: Chronic mucocutaneous candidiasis
  evidence:
  - reference: PMID:20123959
    reference_title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED,
      or autoimmune polyendocrine syndrome 1), CMC is often the first sign
    explanation: This establishes CMC as an early APS-1 manifestation.
- name: Vitiligo
  category: Dermatologic
  description: >-
    Autoimmune melanocyte loss can accompany endocrine autoimmunity and is one
    of the non-endocrine manifestations represented in the syndrome spectrum.
  phenotype_term:
    preferred_term: Vitiligo
    term:
      id: HP:0001045
      label: Vitiligo
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
      thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
      pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
    explanation: The review lists vitiligo within the APS-1 spectrum.
- name: Atrophic Gastritis
  category: Gastrointestinal
  description: >-
    Autoimmune gastric injury can produce atrophic gastritis and may progress to
    vitamin B12 deficiency or pernicious anemia. It is a non-endocrine component,
    not part of every traditional subtype definition.
  phenotype_term:
    preferred_term: Atrophic gastritis
    term:
      id: HP:0002582
      label: Atrophic gastritis
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      APS-1 is often accompanied by hypogonadism, type 1 diabetes, autoimmune
      thyroiditis, vitiligo, alopecia, asplenia, pneumonitis, gastritis,
      pernicious anemia, and intestinal dysfunction, nephritis, and hepatitis.
    explanation: The review identifies gastritis and pernicious anemia among APS-1 manifestations.
- name: Alopecia
  category: Dermatologic
  description: >-
    Autoimmune hair loss can accompany autoimmune polyendocrinopathy, including
    APS-1, and has been used as a manifestation-specific endpoint in current
    APS-1 JAK-inhibitor research.
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  evidence:
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ruxolitinib treatment of five patients with APS-1 led to decreased levels
      of T-cell–derived interferon-γ, normalized interferon-γ and CXCL9 levels,
      and remission of alopecia
    explanation: The pilot study directly documents alopecia and its remission during APS-1 treatment.
- name: Primary Hypogonadism
  category: Endocrine
  description: >-
    Autoimmune gonadal failure can present as primary ovarian or testicular
    hypogonadism. Reported prevalence varies across component-disease cohorts and
    is not assigned an umbrella-wide frequency.
  phenotype_term:
    preferred_term: Primary hypogonadism
    term:
      id: HP:0000135
      label: Hypogonadism
  evidence:
  - reference: PMID:12050123
    reference_title: "Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A varied prevalence of hypergonadotropic hypogonadism in patients with AD
      and value of steroid-producing cells autoantibodies reactive with steroid
      17alpha-hydroxylase or P450 side-chain cleavage enzyme as markers of this
      disease has been discussed.
    explanation: This supports autoimmune primary gonadal failure and explicitly cautions that prevalence varies.
genetic:
- name: AIRE
  gene_term:
    preferred_term: AIRE
    term:
      id: hgnc:360
      label: AIRE
  association: Biallelic pathogenic variants cause APS-1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Type 1
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:35690244
      reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Autoimmune polyendocrine syndrome type 1 (APS-1) is an autosomal
        recessive hereditary pathology
      explanation: The review explicitly states autosomal recessive inheritance.
  notes: >-
    Standard exon and splice-boundary testing can miss pathogenic deep intronic
    variants. A 2024 cohort identified an AIRE pseudoexon-forming founder variant
    in clinically diagnosed patients lacking biallelic findings on conventional
    testing.
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      APS-1 occurs because of mutations in the autoimmune regulator (AIRE) gene
    explanation: This supports the causal AIRE relationship for APS-1.
  - reference: PMID:39292801
    reference_title: A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Through whole-genome sequencing, we identified a deep intronic AIRE variant
      (c.1504-818 G>A) cosegregating with the disease in all 17 patients.
    explanation: This demonstrates a pathogenic deep intronic mechanism missed by conventional exon-focused testing.
- name: HLA-DRB1
  gene_term:
    preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  association: HLA class II susceptibility in adult APS
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  subtype: Type 2
  notes: >-
    HLA class II alleles increase risk for the component autoimmune diseases but
    neither establish an APS diagnosis nor act as sufficient causes.
  evidence:
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A defect resides in one of the genes of the HLA locus which, in concert
      with other gene(s), results in susceptibility.
    explanation: This supports a risk-factor rather than monogenic-causal relationship.
- name: CTLA4
  gene_term:
    preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  association: Immune-regulatory susceptibility in adult APS
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  subtype: Type 2
  notes: Common CTLA4 variation contributes susceptibility; this entry does not conflate that association with monogenic CTLA4 haploinsufficiency.
  evidence:
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These are certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4)
      gene, and the protein tyrosine phosphatase non-receptor type 22 (PTPN22)
      genes on chromosomes 6, 2, and 1, respectively.
    explanation: This identifies CTLA4 among type 2 susceptibility genes.
- name: PTPN22
  gene_term:
    preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  association: Immune-regulatory susceptibility in adult APS
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  subtype: Type 2
  notes: PTPN22 variation modifies autoimmune risk but is not sufficient to cause the syndrome.
  evidence:
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These are certain HLA genes, the cytotoxic T-lymphocyte antigen (CTLA-4)
      gene, and the protein tyrosine phosphatase non-receptor type 22 (PTPN22)
      genes on chromosomes 6, 2, and 1, respectively.
    explanation: This identifies PTPN22 among type 2 susceptibility genes.
biochemical:
- name: Organ-specific endocrine autoantibodies
  presence: PRESENT
  notes: >-
    Antibodies such as adrenal cortex/21-hydroxylase, thyroid, or islet
    autoantibodies can confirm an autoimmune context and identify risk for a
    future component disease. Their presence is not equivalent to established
    gland failure, and they are modeled as biomarkers rather than generic agents
    of tissue destruction.
  readouts:
  - target: Organ-Specific Autoreactive T-Cell Effector Injury
    relationship: CORRELATES_WITH
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Organ-specific autoantibodies support loss of tolerance to the corresponding
      tissue, but the antibody signal does not by itself establish functional failure.
    evidence:
    - reference: PMID:23159534
      reference_title: Polyglandular autoimmune syndrome type II.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Autoantibodies to the various endocrine and non-endocrine tissues not
        only offer a diagnostic clue to the autoimmune nature of diseases
      explanation: This directly supports their diagnostic biomarker role.
  - target: Organ-Specific Autoreactive T-Cell Effector Injury
    relationship: PREDICTS
    direction: PRESENT_ABSENT
    endpoint_context: PROGNOSTIC
    interpretation: >-
      In an at-risk patient, a component-specific autoantibody may precede
      clinical endocrine failure, with predictive value depending on antigen,
      age, titer, and functional testing.
    evidence:
    - reference: PMID:12050123
      reference_title: "Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In the course of natural history of autoimmune AD, the presence of
        adrenal cortex and/or steroid 21-hydroxylase autoantibodies identified
        patients at risk to develop AD.
      explanation: This supports a predictive, not necessarily destructive, role for adrenal autoantibodies.
  evidence:
  - reference: PMID:20685079
    reference_title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In autoimmune adrenal deficiency, autoantibodies target the 21-hydroxylase
      (21OH) protein. However, it is presumed that autoreactive T cells, rather
      than antibodies, are the main effectors of adrenal gland destruction
    explanation: This is the evidence boundary underlying biomarker rather than generic effector modeling.
- name: APS-1 neutralizing Th17-cytokine autoantibodies
  presence: PRESENT
  notes: >-
    Anti-IL-17A, anti-IL-17F, and anti-IL-22 antibodies are APS-1-associated
    biomarkers with a mechanistically distinct relationship to impaired
    antifungal defense. They should not be generalized to adult types 2-4.
  readouts:
  - target: Neutralizing Th17-Cytokine Autoantibodies and Mucosal Antifungal Failure
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Neutralizing anti-IL-17F/IL-22 activity reports the APS-1 mucosal
      antifungal-failure mechanism, especially in a patient with CMC.
    evidence:
    - reference: PMID:20123959
      reference_title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The autoantibodies preceded the CMC in all informative cases.
      explanation: Temporal precedence supports a mechanistic biomarker interpretation.
  evidence:
  - reference: PMID:20123959
    reference_title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our multicenter survey revealed neutralizing autoantibodies against IL-17A
      (41%), IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients,
      especially those with CMC.
    explanation: This supports the APS-1 anti-cytokine biomarker profile.
diagnosis:
- name: Clinical assessment of component diseases
  description: >-
    Establish the component endocrine diagnoses and determine whether at least
    two failures are autoimmune. Clinical pattern, age at onset, candidiasis,
    non-endocrine autoimmunity, treatment exposures, and family history guide
    classification; a traditional APS label is not a substitute for confirming
    each gland's functional state.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: >-
    Two autoimmune-induced endocrine failures support the umbrella diagnosis;
    the component pattern and genetic context determine the subtype assignment.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune polyglandular diseases (APD) are defined as the presence of two
      autoimmune -induced endocrine failures.
    explanation: This supplies the operational syndrome-level threshold.
- name: Longitudinal endocrine functional testing
  description: >-
    Measure hormone, electrolyte, glucose, and related gland-function markers
    according to the patient's current components and risks. Repeat testing is
    necessary because new endocrine failure can appear after a variable interval.
  diagnosis_term:
    preferred_term: circulating hormone measurement
    term:
      id: NCIT:C74742
      label: Hormone Measurement
  results: >-
    Functional deficiency or stimulation-test failure establishes a component
    endocrinopathy; normal testing at one time point does not end surveillance.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This requires that patients at risk be regularly screened for subclinical
      endocrinopathies prior to clinical manifestation.
    explanation: This supports repeated functional screening before overt disease.
- name: Component-specific autoantibody testing
  description: >-
    Measure organ-specific autoantibodies to support autoimmune attribution and
    risk stratification. Interpret results with symptoms and gland-function tests;
    antibody positivity alone is not equivalent to destructive endocrine failure.
  diagnosis_term:
    preferred_term: antibody titer measurement
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    A positive component-specific autoantibody supports autoimmune disease or
    future risk, with performance dependent on the antigen and clinical context.
  evidence:
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the determination of autoantibodies can be useful to predict the risk of
      disease manifestation and to confirm the autoimmune disease in some cases.
    explanation: This explicitly supports both predictive and confirmatory use with qualified certainty.
- name: AIRE molecular genetic testing for suspected APS-1
  description: >-
    Sequence AIRE when early onset, candidiasis, hypoparathyroidism, adrenal
    insufficiency, or other features suggest APS-1. If clinical suspicion remains
    high after conventional exon/splice testing, methods capable of detecting
    deep intronic or structural variants may be required.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  results: >-
    Biallelic pathogenic AIRE variants confirm APS-1; a negative conventional
    panel does not exclude deep intronic disease.
  evidence:
  - reference: PMID:35690244
    reference_title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Analysis of the AIRE gene is the main diagnostic method for early detection of APS-1
    explanation: This supports AIRE analysis in the APS-1 diagnostic pathway.
  - reference: PMID:39292801
    reference_title: A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      identified 17 patients (16%) from 14 kindreds lacking biallelic AIRE
      variants in exons or flanking intronic regions
    explanation: This demonstrates the limitation of conventional exon and flanking-intron testing in a clinically diagnosed cohort.
differential_diagnoses:
- name: IPEX syndrome
  description: >-
    IPEX can present in infancy with systemic autoimmunity, enteropathy, eczema,
    and endocrine disease, especially type 1 diabetes. Male sex, severe early
    enteropathy/dermatitis, regulatory-T-cell abnormalities, and a hemizygous
    FOXP3 variant distinguish it from traditional APS-1 or adult APS.
  disease_term:
    preferred_term: immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome
    term:
      id: MONDO:0010580
      label: immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome
  distinguishing_features:
  - Usually begins in the first year of life in an affected male.
  - Enteropathy and eczematous dermatitis accompany endocrinopathy.
  - A hemizygous pathogenic FOXP3 variant establishes the X-linked diagnosis.
  evidence:
  - reference: PMID:20301297
    reference_title: IPEX Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked)
      syndrome is characterized by systemic autoimmunity, typically beginning in
      the first year of life, which includes the triad of enteropathy
      (manifesting as malabsorption and watery diarrhea), endocrinopathy (most
      commonly type 1 insulin-dependent diabetes mellitus), and eczematous dermatitis.
    explanation: This defines the early clinical pattern that distinguishes IPEX.
- name: Multiple endocrine neoplasia type 2
  description: >-
    MEN2 produces multiple endocrine abnormalities through neoplasia rather than
    multiglandular autoimmunity. Medullary thyroid carcinoma and pheochromocytoma,
    autosomal dominant inheritance, and a pathogenic RET variant favor MEN2.
  disease_term:
    preferred_term: multiple endocrine neoplasia type 2
    term:
      id: MONDO:0019003
      label: multiple endocrine neoplasia type 2
  distinguishing_features:
  - Endocrine tumors rather than autoimmune gland failure dominate.
  - Medullary thyroid carcinoma with pheochromocytoma is characteristic.
  - Pathogenic RET variants confer autosomal dominant disease.
  evidence:
  - reference: PMID:11786689
    reference_title: Multiple endocrine neoplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MEN2 is characterized by medullary thyroid carcinoma (MTC) in association with phaeochromocytoma.
    explanation: This states the neoplastic combination separating MEN2 from autoimmune polyendocrinopathy.
- name: Immune checkpoint inhibitor-induced APS-2-like endocrinopathy
  description: >-
    Cancer immunotherapy can produce two or more immune-related endocrine
    failures that resemble APS-2. The temporal relationship to checkpoint
    inhibition and its acquired adverse-event context distinguish this from
    spontaneous familial or polygenic APS, while the same emergencies still
    require prompt recognition.
  distinguishing_features:
  - Begins during or after CTLA-4, PD-1, or PD-L1 checkpoint-inhibitor exposure.
  - Is an acquired immune-related adverse event rather than an inherited syndrome.
  - Diabetic ketoacidosis or adrenal crisis may be the presenting emergency.
  evidence:
  - reference: PMID:32905579
    reference_title: "ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we provide an overview of all published and reported cases (n = 30) of ICPis-induced APS-2.
    explanation: This establishes a documented acquired APS-2-like treatment complication.
- name: Isolated autoimmune endocrinopathy
  description: >-
    A single autoimmune endocrine disease does not yet meet the umbrella
    definition. It may remain isolated or represent an incomplete stage before a
    second component appears, so longitudinal surveillance is more appropriate
    than premature syndrome assignment.
  distinguishing_features:
  - Only one autoimmune-induced endocrine failure is currently established.
  - A second gland must be confirmed before the umbrella definition is met.
  evidence:
  - reference: PMID:31606344
    reference_title: Autoimmune polyglandular diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune polyglandular diseases (APD) are defined as the presence of two
      autoimmune -induced endocrine failures.
    explanation: The two-failure definition distinguishes isolated disease from the umbrella syndrome.
treatments:
- name: Component-Specific Hormone Replacement
  action_category: THERAPEUTIC
  description: >-
    Replace hormones according to each confirmed gland failure, including
    glucocorticoid/mineralocorticoid, thyroid hormone, insulin, calcium/active
    vitamin D or parathyroid hormone strategies, and sex-steroid replacement as
    appropriate. Replacement treats the endocrine consequence; it does not
    restore immune tolerance or prevent every future component.
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: NCIT:C15445
      label: Hormone Therapy
  target_phenotypes:
  - preferred_term: Adrenal Insufficiency
    term:
      id: HP:0000846
      label: Adrenal insufficiency
  - preferred_term: Hashimoto Thyroiditis
    term:
      id: HP:0000872
      label: Hashimoto thyroiditis
  - preferred_term: Type 1 Diabetes Mellitus
    term:
      id: HP:0100651
      label: Type I diabetes mellitus
  - preferred_term: Hypoparathyroidism
    term:
      id: HP:0000829
      label: Hypoparathyroidism
  - preferred_term: Primary Hypogonadism
    term:
      id: HP:0000135
      label: Hypogonadism
  evidence:
  - reference: PMID:34790633
    reference_title: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The goals of replacement treatment include the prevention of hypocalcemic crises
    explanation: The APS-1 management review supports consequence-directed replacement for hypoparathyroidism.
  - reference: PMID:34790633
    reference_title: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      optimal pubertal development and growth in patients with hypogonadism
    explanation: This supports timely replacement for autoimmune gonadal failure.
- name: Adrenal Stress Dosing and Emergency Preparedness
  action_category: THERAPEUTIC
  description: >-
    Patients with adrenal insufficiency require stress-dose education, access to
    injectable hydrocortisone, and medical-alert identification to reduce risk
    during febrile illness, procedures, vomiting, or other physiologic stress.
  treatment_term:
    preferred_term: adrenal hormone replacement therapy
    term:
      id: NCIT:C15599
      label: Hormone Replacement Therapy
  target_phenotypes:
  - preferred_term: Adrenal Insufficiency
    term:
      id: HP:0000846
      label: Adrenal insufficiency
  evidence:
  - reference: PMID:34790633
    reference_title: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      access to parenteral hydrocortisone for acute stress dosing and
    explanation: This directly supports the emergency-preparedness action.
- name: Antifungal Therapy for APS-1 Candidiasis
  action_category: THERAPEUTIC
  description: >-
    Treat active mucosal candidiasis in APS-1 with a topical or systemic
    antifungal selected according to site, severity, recurrence, culture, and
    susceptibility. Recurrent disease may require secondary prophylaxis;
    prolonged azole exposure requires attention to resistance and toxicity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fluconazole
      term:
        id: CHEBI:46081
        label: fluconazole
  target_phenotypes:
  - preferred_term: Chronic Mucocutaneous Candidiasis
    term:
      id: HP:0002728
      label: Chronic mucocutaneous candidiasis
  evidence:
  - reference: PMID:34790633
    reference_title: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acute episodes of mucosal candidiasis respond well to induction therapy
      for four weeks
    explanation: This directly supports antifungal induction for active APS-1 mucosal candidiasis.
- name: Ruxolitinib for Severe APS-1 Autoimmune Manifestations
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Ruxolitinib is an investigational, mechanism-directed option for selected
    severe APS-1 manifestations. The published human evidence is an uncontrolled
    five-patient pilot with promising multiorgan responses; efficacy,
    manifestation-specific benefit, infection risk, and long-term safety require
    prospective trial confirmation. It is not established therapy for adult
    types 2-4.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ruxolitinib
      term:
        id: CHEBI:66919
        label: ruxolitinib
  target_mechanisms:
  - target: APS-1 Interferon-γ–JAK-STAT Effector Program
    treatment_effect: INHIBITS
    description: JAK1/2 inhibition suppresses the excessive interferon-γ–STAT1 program identified in APS-1.
    evidence:
    - reference: PMID:38810185
      reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice
        normalized interferon-γ responses and averted T-cell infiltration and
        damage in organs.
      explanation: Pharmacologic and genetic perturbations support the targeted mechanism in the Aire-deficient mouse.
  target_phenotypes:
  - preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  - preferred_term: Atrophic Gastritis
    term:
      id: HP:0002582
      label: Atrophic gastritis
  - preferred_term: Chronic Mucocutaneous Candidiasis
    term:
      id: HP:0002728
      label: Chronic mucocutaneous candidiasis
  - preferred_term: Hashimoto Thyroiditis
    term:
      id: HP:0000872
      label: Hashimoto thyroiditis
  evidence:
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ruxolitinib treatment of five patients with APS-1 led to decreased levels
      of T-cell–derived interferon-γ, normalized interferon-γ and CXCL9 levels,
      and remission of alopecia, oral candidiasis, nail dystrophy, gastritis,
      enteritis, arthritis, Sjögren’s-like syndrome, urticaria, and thyroiditis.
    explanation: This reports the five-patient mechanistic and clinical response signal.
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: JAK inhibition with ruxolitinib in five patients showed promising results.
    explanation: The authors' conclusion is explicitly promising rather than definitive, supporting investigational framing.
clinical_trials:
- name: NCT05398809
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Recruiting open-label phase 2 study of oral ruxolitinib for severe alopecia
    areata in people aged 12-65 years with APECED. The registry listed an
    estimated enrollment of 70 and status verification in June 2026 at the
    2026-07-21 audit. The endpoint is manifestation-specific hair regrowth, not
    proof of syndrome-wide disease modification.
  evidence:
  - reference: clinicaltrials:NCT05398809
    reference_title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To see if a study drug (ruxolitinib) can help hair regrowth in people with
      APECED-associated AA and if it can improve other symptoms caused by the
      immune system s attack to the body.
    explanation: The registry states the ruxolitinib objective and APECED-associated alopecia population.
- name: NCT07202598
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Recruiting randomized stepped-wedge phase 2 study of the interferon-γ
    antibody emapalumab for APECED enteritis. The registry listed an estimated
    enrollment of 10 and status verification in December 2025 at the 2026-07-21
    audit. It tests one severe APS-1 manifestation rather than adult APS types.
  evidence:
  - reference: clinicaltrials:NCT07202598
    reference_title: A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To test a drug (emapalumab) in people with enteritis caused by APECED.
    explanation: The registry states the intervention, disease, and manifestation-specific objective.
- name: NCT05578105
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Observational Taiwan study of APS type 2 epidemiology, clinical
    characteristics, and genetic variation, with estimated enrollment of 650.
    The recruiting status had last been verified in October 2022 at the
    2026-07-21 audit, so operational currency is uncertain and no intervention
    efficacy can be inferred.
  evidence:
  - reference: clinicaltrials:NCT05578105
    reference_title: Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this study, we will observe the epidemiology, clinical characteristics,
      and genetic variants of APS II in Taiwan.
    explanation: The registry defines this as an observational adult APS-2 study.
- name: NCT05716607
  phase: NOT_APPLICABLE
  status: WITHDRAWN
  description: >-
    Randomized crossover study planned to examine glycemic variability in people
    treated with both insulin and hydrocortisone. The registry was withdrawn
    before enrollment with an actual enrollment of zero at the 2026-07-21 audit;
    it therefore supplies no outcome evidence.
  evidence:
  - reference: clinicaltrials:NCT05716607
    reference_title: "Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The aim of INS.CORT trial is
    explanation: The registry documents the planned combined insulin/hydrocortisone study; its withdrawn status precludes efficacy inference.
animal_models:
- species: mouse
  genotype: Aire-/- knockout mouse
  category: Germline knockout model of APS-1 central-tolerance failure
  genes:
  - preferred_term: AIRE
    term:
      id: hgnc:360
      label: AIRE
  description: >-
    Aire-null mice develop multiorgan lymphocytic infiltrates, circulating
    autoantibodies, altered peripheral T-cell responses, and infertility. The
    model is mechanistically informative for AIRE-dependent tolerance and
    interferon perturbation but does not reproduce the entire human APECED
    phenotype.
  associated_phenotypes:
  - Multiorgan lymphocytic infiltration
  - Circulating autoantibodies
  - Infertility
  evidence:
  - reference: PMID:11854172
    reference_title: Aire deficient mice develop multiple features of APECED phenotype and show altered immune response.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The Aire-/- mice develop normally; however, autoimmune features of APECED
      in Aire-/- mice are evident, including multiorgan lymphocytic infiltration,
      circulating autoantibodies and infertility.
    explanation: This directly identifies the principal phenotypes of the knockout model.
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Ifng ablation or ruxolitinib-induced JAK-STAT blockade in Aire-/- mice
      normalized interferon-γ responses and averted T-cell infiltration and
      damage in organs.
    explanation: This establishes the model's use for causal interferon-pathway perturbation.
datasets:
- accession: geo:GSE225460
  title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
  description: >-
    Human bulk RNA-sequencing dataset of oral mucosal biopsies from people with
    APECED and healthy donors, including a pre/post-ruxolitinib series. It is
    directly relevant to the tissue interferon-γ/CXCL9 mechanism but is small and
    APS-1-specific.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: oral mucosal biopsy
    term:
      id: UBERON:0003729
      label: mouth mucosa
    tissue_term:
      preferred_term: oral mucosa
      term:
        id: UBERON:0003729
        label: mouth mucosa
  sample_count: 8
  conditions:
  - APECED oral mucosa
  - Healthy donor oral mucosa
  - Pre/post-ruxolitinib APS-1 tissue series
  publication: PMID:38810185
  evidence:
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with APS-1 had enhanced interferon-γ responses in blood and in all
      examined autoimmunity-affected tissues.
    explanation: The associated publication supports transcriptomic interrogation of affected human tissues.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225460
- accession: geo:GSE243061
  title: Tregs in autoimmune polyendocrine syndrome type I
  description: >-
    Single-cell transcriptomic study of regulatory T cells sorted from peripheral
    blood in four APS-1 participants and four healthy controls, with ex-vivo
    expansion analyses. GEO notes that raw patient data are withheld for privacy,
    which limits unrestricted reanalysis.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
  - preferred_term: peripheral blood regulatory T cells
    term:
      id: CL:0000815
      label: regulatory T cell
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
    cell_type_term:
      preferred_term: regulatory T cell
      term:
        id: CL:0000815
        label: regulatory T cell
  sample_count: 8
  conditions:
  - APS-1
  - Healthy control
  publication: PMID:38632993
  evidence:
  - reference: PMID:38632993
    reference_title: Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have used single cell transcriptomics to characterize regulatory T
      cells (Tregs) sorted directly from blood and from in vitro expanded Tregs
      in APS-1 patients compared to healthy controls.
    explanation: The publication directly describes the dataset's cell population, assay, and comparison.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243061
- accession: geo:GSE254003
  title: A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion
  description: >-
    Bulk RNA-sequencing of human TEC4D6 thymic epithelial cells transfected with
    wild-type AIRE, pseudoexon-containing mutant AIRE, or GFP control. This is a
    mechanistic cell-line dataset rather than patient tissue and should not be
    used to estimate clinical expression frequencies.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: TEC4D6 thymic epithelial cell line
    term:
      id: CL:0002293
      label: epithelial cell of thymus
    tissue_term:
      preferred_term: thymus
      term:
        id: UBERON:0002370
        label: thymus
    cell_type_term:
      preferred_term: thymic epithelial cell
      term:
        id: CL:0002293
        label: epithelial cell of thymus
  sample_count: 12
  conditions:
  - Wild-type AIRE transfection
  - Deep-intronic-variant AIRE transfection
  - GFP control transfection
  publication: PMID:39292801
  evidence:
  - reference: PMID:39292801
    reference_title: A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Through protein modeling and transcriptomic analyses of AIRE-transfected
      human embryonic kidney 293 and thymic epithelial cell 4D6 cells, we showed
      that this variant alters the carboxyl terminus of the AIRE protein,
      abrogating its function.
    explanation: The publication identifies the cell systems and transcriptomic purpose represented by the GEO series.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254003
discussions:
- discussion_id: autoimmune_polyendocrinopathy_classification_boundary
  prompt: >-
    Should autoimmune polyendocrinopathy continue to use the traditional types
    1-4 as one classification, or should monogenic immune-dysregulation syndromes
    such as IPEX be integrated as peer APS types?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - has_subtypes#Type 1
  - has_subtypes#Type 2
  - has_subtypes#Type 3
  - has_subtypes#Type 4
  rationale: >-
    The traditional four-type scheme is embedded in MONDO and adult endocrine
    literature, but newer pediatric reviews use a three-group framework of
    APS-1, APS-2, and IPEX. These groupings mix molecular etiologies and clinical
    combinations, so subtype counts are classification-dependent rather than a
    settled natural taxonomy.
  evidence:
  - reference: PMID:36980146
    reference_title: Autoimmune Polyendocrine Syndromes in the Pediatric Age.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three types of APSs are reported, including both monogenic and
      multifactorial, heterogeneous disorders.
    explanation: This recent review explicitly uses a three-type pediatric framework.
  - reference: PMID:33958142
    reference_title: Autoinmune polyendocrinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SPA type 3 is characterized by autoimmune thyroid disease and other
      autoimmune disease, excluding Addison's disease and hypoparathyroidism
    explanation: This review documents continued use of the traditional type 3 category.
- discussion_id: organ_autoantibody_biomarker_vs_effector
  prompt: >-
    For each component endocrinopathy, which autoantibodies are predictive or
    diagnostic biomarkers, and which—if any—directly mediate tissue injury rather
    than marking a T-cell-driven response?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - biochemical#Organ-specific endocrine autoantibodies
  - pathophysiology#Organ-Specific Autoreactive T-Cell Effector Injury
  rationale: >-
    Collapsing all autoantibodies into one destructive mechanism overstates
    evidence and obscures the functionally distinct APS-1 anti-cytokine
    antibodies. Antigen-, organ-, and stage-specific longitudinal studies are
    needed to separate prediction from effector causality.
  proposed_experiments:
  - experiment_id: exp_aps_component_antibody_tcell_longitudinal
    name: Prospective paired autoantibody and autoreactive T-cell study
    description: >-
      Enroll antibody-positive patients before gland failure and repeatedly
      measure antibody titer/function, antigen-specific CD4/CD8 repertoires,
      gland-function tests, and clinical conversion. Test whether antibody
      changes add causal or predictive information beyond T-cell responses.
    experiment_type:
      preferred_term: prospective longitudinal immune-phenotyping study
    decision_criterion: >-
      Distinguish biomarkers that only correlate with conversion from antibodies
      whose functional activity independently precedes and predicts tissue injury.
  evidence:
  - reference: PMID:20685079
    reference_title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, it is presumed that autoreactive T cells, rather than antibodies,
      are the main effectors of adrenal gland destruction
    explanation: This supplies the adrenal example motivating the distinction.
  - reference: PMID:23159534
    reference_title: Polyglandular autoimmune syndrome type II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoantibodies to the various endocrine and non-endocrine tissues not only
      offer a diagnostic clue to the autoimmune nature of diseases but also can
      be used to identify asymptomatic individuals who are at risk
    explanation: This supports diagnostic and predictive utility without claiming direct injury.
- discussion_id: aps1_interferon_trial_and_cross_subtype_generalizability
  prompt: >-
    Does interferon-γ/JAK-STAT inhibition provide durable, safe, controlled
    benefit across APS-1 manifestations, and does the same effector program apply
    to polygenic adult APS types 2-4?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#APS-1 Interferon-γ–JAK-STAT Effector Program
  - treatments#Ruxolitinib for Severe APS-1 Autoimmune Manifestations
  rationale: >-
    Causal mouse perturbations and a five-patient human pilot are compelling but
    cannot define long-term safety, comparative efficacy, organ-specific response,
    or applicability beyond AIRE deficiency.
  proposed_experiments:
  - experiment_id: exp_controlled_aps1_ifng_jak_trial
    name: Controlled APS-1 interferon-pathway trial with adult APS comparator profiling
    description: >-
      Randomize manifestation-defined APS-1 participants to interferon-γ or JAK
      pathway blockade versus control, with prespecified clinical endpoints,
      infection monitoring, tissue IFN-γ/pSTAT1/CXCL9 pharmacodynamics, and
      long-term follow-up. Profile the same pathway in untreated APS-2/3 cohorts
      without assuming treatment eligibility.
    experiment_type:
      preferred_term: randomized mechanistic clinical trial
    decision_criterion: >-
      Confirm clinically meaningful benefit with an on-target tissue response and
      acceptable safety, then determine whether adult APS shares the baseline
      pathway signature.
  evidence:
  - reference: PMID:38810185
    reference_title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: JAK inhibition with ruxolitinib in five patients showed promising results.
    explanation: The small pilot size and qualified conclusion define the evidence gap.
- discussion_id: aire_mouse_human_phenotype_mismatch
  prompt: >-
    Which APS-1 mechanisms and organ phenotypes are faithfully reproduced by the
    Aire-null mouse, and which human manifestations require rat, organoid, or
    patient-tissue models?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#AIRE-Dependent Central Tolerance Failure
  - animal_models#Aire-/- knockout mouse
  rationale: >-
    Aire-null mice establish central-tolerance and interferon-effector biology,
    but the model incompletely reproduces human APECED's organ distribution and
    clinical phenotype. Translational conclusions should therefore be separated
    into conserved mechanism versus model-specific disease expression.
  proposed_experiments:
  - experiment_id: exp_aire_cross_species_multiorgan_atlas
    name: Cross-species AIRE-deficiency multiorgan immune atlas
    description: >-
      Generate matched single-cell and spatial immune profiles from Aire-null
      mouse and rat target organs and available human APS-1 biopsies, with common
      antigen-specific T-cell, interferon, and tissue-injury readouts.
    experiment_type:
      preferred_term: cross-species single-cell and spatial profiling
    decision_criterion: >-
      Identify conserved cell states and causal pathways separately from
      species-specific organ tropism and manifestations.
  evidence:
  - reference: PMID:33729987
    reference_title: AIRE deficiency, from preclinical models to human APECED disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, these murine models poorly recapitulate all phenotypic aspects of human APECED.
    explanation: The review explicitly identifies incomplete human-phenotype fidelity of the mouse models.
- discussion_id: adult_aps_trials_and_public_omics_gap
  prompt: >-
    Can a longitudinal adult APS type 2-4 cohort provide current natural-history,
    trial-readiness, and public multi-omic resources comparable to emerging APS-1 studies?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - has_subtypes#Type 2
  - has_subtypes#Type 3
  - has_subtypes#Type 4
  - datasets#geo:GSE225460
  - datasets#geo:GSE243061
  rationale: >-
    Exact registry and GEO audits on 2026-07-21 found active interventional work
    concentrated on APS-1 manifestations and the selected public transcriptomic
    datasets concentrated on APS-1. The one selected APS-2 registry is
    observational and had stale status verification. This limits cross-subtype
    mechanism comparison and adult trial design.
  proposed_experiments:
  - experiment_id: exp_adult_aps_longitudinal_multiomic_cohort
    name: Longitudinal adult APS type 2-4 natural-history and multi-omic cohort
    description: >-
      Recruit well-phenotyped type 2-4 participants and at-risk relatives across
      centers; collect serial gland-function, autoantibody, antigen-specific
      T-cell, genotype, transcriptome, and outcome data under a public
      controlled-access data plan.
    experiment_type:
      preferred_term: longitudinal multi-omic natural-history study
    decision_criterion: >-
      Define reproducible molecular endotypes and prospective conversion markers
      that can support adult APS prevention or mechanism-directed trials.
  evidence:
  - reference: clinicaltrials:NCT05578105
    reference_title: Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this study, we will observe the epidemiology, clinical characteristics,
      and genetic variants of APS II in Taiwan.
    explanation: This is observational rather than an adult APS intervention trial.
  - reference: PMID:38632993
    reference_title: Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have used single cell transcriptomics to characterize regulatory T
      cells (Tregs) sorted directly from blood and from in vitro expanded Tregs
      in APS-1 patients compared to healthy controls.
    explanation: The selected public single-cell resource is specifically APS-1, illustrating the subtype imbalance.
references:
- reference: PMID:29562162
  title: Autoimmune Polyendocrine Syndromes.
- reference: PMID:31606344
  title: Autoimmune polyglandular diseases.
- reference: PMID:23159534
  title: Polyglandular autoimmune syndrome type II.
- reference: PMID:33958142
  title: Autoinmune polyendocrinopathy.
- reference: PMID:12050123
  title: "Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction."
- reference: PMID:35690244
  title: "Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach."
- reference: PMID:20685079
  title: "21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease."
- reference: PMID:20123959
  title: Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
- reference: PMID:38810185
  title: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
- reference: PMID:39292801
  title: A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
- reference: PMID:38632993
  title: Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1.
- reference: PMID:11854172
  title: Aire deficient mice develop multiple features of APECED phenotype and show altered immune response.
- reference: PMID:33729987
  title: AIRE deficiency, from preclinical models to human APECED disease.
- reference: PMID:36980146
  title: Autoimmune Polyendocrine Syndromes in the Pediatric Age.
- reference: PMID:32905579
  title: "ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management."
- reference: PMID:20301297
  title: IPEX Syndrome.
- reference: PMID:11786689
  title: Multiple endocrine neoplasia.
- reference: PMID:34790633
  title: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
- reference: clinicaltrials:NCT05398809
  title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
- reference: clinicaltrials:NCT07202598
  title: A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
- reference: clinicaltrials:NCT05578105
  title: Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
- reference: clinicaltrials:NCT05716607
  title: "Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone"
review_notes: >-
  Re-review preserved the legacy updated_date and treated MONDO:0017278 as an
  umbrella rather than duplicating the separate APS-1/APECED entry. It retained
  four MONDO-linked traditional subtypes while recording the competing
  three-group pediatric classification. The central mechanistic correction was
  to model organ-specific autoantibodies chiefly as diagnostic/predictive
  biomarkers and autoreactive T cells as tissue-damaging effectors; neutralizing
  APS-1 Th17-cytokine antibodies remain a distinct functional mechanism. Trial
  and GEO searches were audited on 2026-07-21: selected active intervention
  trials were APS-1 manifestation-specific, the selected APS-2 study was
  observational with stale status verification, and public mechanistic
  transcriptomic datasets were APS-1-heavy. Ruxolitinib is therefore explicitly
  investigational, based on a five-patient pilot and ongoing phase 2 work. No
  umbrella-wide phenotype frequencies, deterministic adult-APS genetic claims,
  or syndrome-wide disease-modifying treatment claims are made.
📚

References & Deep Research

References

22
PMID:29562162
Autoimmune Polyendocrine Syndromes.
No top-level findings curated for this source.
PMID:31606344
Autoimmune polyglandular diseases.
No top-level findings curated for this source.
PMID:23159534
Polyglandular autoimmune syndrome type II.
No top-level findings curated for this source.
PMID:33958142
Autoinmune polyendocrinopathy.
No top-level findings curated for this source.
PMID:12050123
Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction.
No top-level findings curated for this source.
PMID:35690244
Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach.
No top-level findings curated for this source.
PMID:20685079
21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease.
No top-level findings curated for this source.
PMID:20123959
Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
No top-level findings curated for this source.
PMID:38810185
The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
No top-level findings curated for this source.
PMID:39292801
A deep intronic splice-altering AIRE variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusion.
No top-level findings curated for this source.
PMID:38632993
Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1.
No top-level findings curated for this source.
PMID:11854172
Aire deficient mice develop multiple features of APECED phenotype and show altered immune response.
No top-level findings curated for this source.
PMID:33729987
AIRE deficiency, from preclinical models to human APECED disease.
No top-level findings curated for this source.
PMID:36980146
Autoimmune Polyendocrine Syndromes in the Pediatric Age.
No top-level findings curated for this source.
PMID:32905579
ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.
No top-level findings curated for this source.
PMID:20301297
IPEX Syndrome.
No top-level findings curated for this source.
PMID:11786689
Multiple endocrine neoplasia.
No top-level findings curated for this source.
PMID:34790633
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.
No top-level findings curated for this source.
clinicaltrials:NCT05398809
A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
No top-level findings curated for this source.
clinicaltrials:NCT07202598
A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
No top-level findings curated for this source.
clinicaltrials:NCT05578105
Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
No top-level findings curated for this source.
clinicaltrials:NCT05716607
Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone
No top-level findings curated for this source.